- 111 kev. 1207 kev. 1207

THIS COURSE (10-) IN NO. 2017 VAL. 1884.

THIS LOTE OF A PARTIES IN NO. 1007011/ED)

Hadde by the publithers Intered in the Patistras (10) field (weighted for records published or updated in Chemical Mattraces after Describe In 1995), uses otherwise indicated in the original publication. The AL statem is the expression intellectual property of the The Marical Chemical Society and is property of the additional control of the Americal Society and is property of the discharge on FUL. My dissembnish, distribution, express, or statish of this indicated in the prior written consent of GAS, is stringly problibited.

FILE COVERS 1907 - 16 May 2007 VOL 146 ISS 21 FILE LAST UPDATED: 14 May 2007 (20070514/ED)

ev CAS Information the Policies, enter HELP USAGETERS for details. This file contains CAS Registry Numbers for easy and accurate

2 116

TIE HONGE STREED AT 11:11:11 OR 16 MAY 2007
THE HOAVES DITERED AT 11:11:11 OR 16 MAY 2007
FLEASE SERVICE OF THE TERS OF TOM SERVICE ASTEDIST.
FLEASE SER HELP EMARTISHE TO THE THE SOUTH (ACS)
COPPRISED (C) 2007 MERICAN CHEMICAL SOCIETY (ACS)

THE COURS 100 - 16 Way 100 PM. THE LEGAL CONTINUES.

THE LOCAT URBAIN. IS WAY 2007 (1007015/ED)

THE LOCAT URBAIN. IS WAY 2007 (1007015/ED)

Held by the publishers therefore the Persons after December for records publishers therefore the Continues observed indicated the December 100 PM and so Observed to assist you in searching the bearesten Charlest Goods and the Location of the persons of DML And Continues the Continues on STS. Any dissemination, distributed to assist you in searching clubbase on STS. Any dissemination, distribute consent of COS, is extracted.

FILE COVERS 1907 - 16 May 2007 VOL 146 155 21 FILE LAST UPDATED: 14 May 2007 (20070514/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

** d que 117

4 EM PILE-REGISTRY AND-ON PLU-ON 11351-67-2 OR 71351-64-3 ON 71351-64-1 ON 71351-64-5 ON 71351-64-5 ON 71351-67-5 ON 71351-67-5 ON 71351-71-6 ON 71351-67-2/ON ON CONTRACT TO THE OWN THE OWN TO THE OWN TO THE OWN THE OWN TO THE OWN THE OWN

ES 71551-73-6 WGAPLES GF 4-Thissplatenes, 5-[(2-(4-(1,1-disethylethyl)[1,1'-biphenyl]-3-yl]-18-Pertiled(stol.5-yl]sethylete)-2-thiono-(901) (G. Index 1948)

29 715511-74-1 RCAPLES
GR 4-Thissolidithums, 5-([2-(4-(1,1-dimethylathyl)-2-hydroxy[1,1-biphemyl]-)
yl]-11-benindarol-5-yl]methylams-3-thione-(9GI) (GR DOUR 1998)

THERE ARE IT CITED REPERENCES AVAILABLE FOR RECORD. ALL CITATIONS AVAILABLE IN THE RE P

MCANIA PROPERTY OF THE PROPERT LLT ANSWER 2 OF 2 HCAPLUS COPTRIGHT 2007 ACS ON STH ACCESSICH NUMBER: 2004:531312 HCAPLUS FOIL-LAKE DOCHMEN NUMBER: 141:94293 EFFERENCE COUNT:

TITLE: INVENTOR(S): PAINT ASSIGNEE(S): SOUNCE:

DOCUMENT TYPE:
LANCHARE:
FAMILY ACC. MIN. COUNT: 1
PATENT DIPORMATION:

| MASSIC PARTY | COLO | MATERIA | MA

| 19538.52|
| 11511.-14-3/GB(GR 11511.75-4/GB) GR 711511.75-7/GB(GR 71511.75-6/GB) GR 711511.75-7/GB GR 711511.75-7/GB GR 711511.75-7/GB GR 711511.75-7/GB GR 71511.75-7/GB GR 71511.75-7/GB GR 71511.75-7/GB GR 71511.75-7

May 16, 2007

-> d 117 ibib abs hitstr tot

117 NUSTRE 1 OF 2 HOAPLES CONTRIGHT 2007 ACS OR STHE ACCORDANCE TO CONTRIGHT SHOPLES SHIPLINGS DOCUMENT HOAPLES HOAPLE

Internation of the company of the co

CORPORATE SOURCE:

SOURCE

FUBLISHER: DOCUMENT TYPE: LANGUAGE: AB A novel ben

And the control magning of mall mail translopicitis receptor against a manner and an article of mall mail translopicitis receptor against a moreous section; with state of darks the polluless y exploration of translers of mailst-n-e finals-n-e finals-n-e

711511-68-1 RCAPLES 4-Thiarolidatone, -5 ([2-(6-(3.4-dimethylphenyl)-2-pyridinyl]-1H-benzinddaol-5-yl]methylens)-2-thioxo- (9CI) (CA INDEX KAME)

OURS CORCE(S):

A THREST AT A TAIL 1833)

THE STATE AT THE THREST AT A TAIL 1833

THREST AT THREST AT THREST AT A TAIL 1833

THREST AT T

tic preparation): TMU (Therapeutic use); BIOL (Biological reparation): UEES (Uses) and formulation of non-peptide thrombopolstin minetics for Linumborycopenia)

; 5-[[2-[6-(3,4-dichlorophny])-2-pyridinyl]-1H-l]methylene]-2-thioxo- (9CI) (CA IMDEX NAE) õã

pr 71351.es-3 HCAPLUS
CS 4-Thiatolidizone, 5-{[2-(6-(3.4-dimethylphenyl)-2-pyridimyl]-18bernindarol-5-yl]methylene|-2-thioxo- (9CE) (CA IDDEX NAME)



RP 71351-69-4 ECAPLES GP 3-Propencie ecid, 1-2-(6-(1.).1-disethylethyl)phmyll-2-pyridinyll-1H-marindanol-3-yll-2-methyl-, (28)- (9C1) (CA. IDDEX NAME)

B 71551-70-7 (CQM) (CQM)

80 713511-71-4 ECAPLES CH -This 2015 (1900 Cm. 5 - (12-(4-(3,4-dimethylphemyl) - 2-thiemyl] - 1H-hemitimidasol-5-yilasebylemsi - 2-thiono- (907) (CA 1905) 8000)

ps 71531-72-9 ROLFULS of 4-Thizzoldinone, 5-[[1-[5-[4-(1,1-disethylathyl]phenyl]-2-furnyl]-15-benindian-[-5-yl]methylene]-2-thiono-(57) (CA DORK MANE)



Double bond geometry as shown


May 16, 2007

RM 715511-70-7 RCAPLES OH 4-Thiareolidinose, 5-([2-(5-(3,4-dimethylphemyl)-2-thiemyl]-1H-benzimidateol-5-yllenthylane):2-thioxo- (9CT) (CA DOER NAWE)

ns 113511-71-8 HCAFUG OH + Thiazolidinos, 5-[[2-(4-(),4-diseby]pheny])-2-thiany]]-1H-benzimidasol-5-y]]menylens]-2-thiano-(9CI) (CA. DROEN MARI)



Ed 71531-72-9 HOLFLUS GH 4-Thiazoldidons, 5-[[-15-(4-(1,1-disenthylethyl)phenyl]-2-furanyl]-1H-benindanol-5-tyllmethylenel-2-thiano-(9CT) (CA Dulin NewE)





May 16, 2007

solognomi activity): SPN (Symthetic preparation); ruse; Blot. (Biological study); FREP MEES (thes) of indolyl or benzimidazolyl benzojc acids ma Ti

(4-butylphenyl) -1H-benzimidazol-2-yl] - (CA

924634-62-0 HCMPLUS Bersots ecid. 4-16-(4-butylphenyl)-1H-henzinidazol-2-yl)-2-hydroxy-Bersot wagi 5 5



113 MONEY (OF 2) HOLVILLS COPRIGHT 2007 MAS OR STN
DECORATION (MASS)
1141 124 141 151411 | HOLVILLS HO

CRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMEEDDED NUMBER OF NODES IS 11

REP G1.(0.20) CH2 NODE ATTRIBUTES: DEFAULT HIEVEL IS ATCH DEFAULT ECLEVEL IS LIMITED

-> d ll2 ibib abs hitind hitstr tot

LL2 ANSIGER (1/OF 23 HCAPLUS COPPRIGHT 2007 ACS on STR ACCESSION NUMBER: 2007:201749 HCAPLUS PORTINENT 146:274.22 1 TITLE: Preparation of indolyl or benefit

DIVENTOR (S):

DOCUMENT TIPE: LANGUAGE: FAMILY ACC. NUM. COURT: PATENT INPORMATION: PATENT ASSIGNMEN(S):

DATE 20060815 ER, SW, SY, BZ, CA, CH, ER, BD, ES, FT, GB, GD, APPLICATION NO. 2 2007022 NO 2006-US; 2 2007022 NO 2006-US; 1, AT, AJ, AZ, BA, BB, BG, BI, 1, CZ, DZ, DK, DM, DZ, EC, EZ 10/538.222
Sittis Parmeenticals, Inc., USA
FOT Inc., 40pl., 55 pp.
COMMIS: PARMEENT
PARENT
PA DOCUMENT TIPE: LANGUAGE: FAMILE ACC: NUM: COUNT: PAIRET DIFORMATION: PATENT ASSIGNEE (S): SOURCE:

KARPAT 146:251843

OTHER SOURCE (S): GI

*BLOOD, DISEASE (L) THROMBOCYT

10/538 252

GENUS SEARCH

14 113 181 FILE ACCOUNTS AND OF TRACE TO THE CONTROL O

to 2-fluorophery) hydratination with W + warey homeone a 10219958 of the amendment in process an america of 170 in an in vitro ferration seasy that potenty as mainted of 170 in an in vitro ferration seasy that the action before the interested vital world (more from 170 in and 170 in an interest of parameters of corporation of disease or induced seasoning of the action of the ac

Heraroyelic Compounds (One Heraro Atom))

Compounds (One Heraro Atom)

Benishidatolyl benzoic scid prepn IPO mimetics

Perspenia treatment

C. Onlood 28 G

saase, thrembooytepenis; preparation of indolyl or zimidazolyl benzoic acids as TFO mimerics) disease E

(threshopyments) proparation of inably) or benzind density)
Manuscate and as TO manuscate and transport and transp

The title compde 1 [11], No. 18 of the industriation of althy) 12 - Considerable 1 [11], No. 18 of the industriation of althy 12 - Considerable 1 [12], No. 18 of the industrial of the industri

8 =

embooytopeois, druq-induced; preparation of substituted imidatoles and analogs as sirtuin modulators useful in treatm prevention of diseases) same, threshooytopmens, drug-induced, preparation of tituted benishdatoles and analogs as sirtuin modulators tent and prevention of diseases) disease

embosytopenic; preparation of substituted and analogs as sirtuin modulators useful in treatment

672330-71-1P 717120-17-7P 134291-67-5P 153343-62-5P 248583-16-6P
-1P 303441-62-3P
-5P 31255-64-5P 312742-54-4P
-6F 33376-91-3P 31404-34-1P

925432-11-7P	925432-12-8P	925432-13-9P	925432-13-9P 925432-14-0P	925432-15-1P
925432-16-2P	925432-18-4P	925432-18-4P 925437-19-5P 92543X-20-8P	34 X - 20- EP	
925432-21-99	925432-22-0P	925412-23-1P	925432-24-2P	925432-25-3P
925432-26-4P	925432-27-59	925432-28-6P	925432-29-7P	925432: 30-0P
925432-31-1P	925432-32-2P	925432-33-39	925432-34-4P	925412-15-5P
925432-36-6P	925432-37-7P	925432-37-7P 925432-39-6P	325432-39-9P	
925432-40-2P	925432-41-38	925432-42-4P	925432-43-5P	925412-44-6P
925432-45-7P	925432-46-82	925432-47-92	925432-48-0P	925432-49-1P
925432-50-4P	925432-S1-SP	925432-52-6P	925432-53-7P	925432-54-BP
925432-55-99	925432-56-0P	925432-57-1P	925432-58-2P	925432-59-3P
925432-60-6P	925432-61-79	925432-62-82	925432-63-99	925432-64-0P
925432-65-1P	925432-66-2P	925432-67-38	925432-68-4P	925432-69-5P
925432-70-BP	925432-71-9P	925432-72-0P	925432-73-1P	925432-74-2P
925432-75-3P	925432-76-4P	925432-77-5P	925432-78-6P	925432-79-7P
925432-80-0P	925432-81-1P	925432-82-22	925432-83-3P	925432-84-4P
925432-85-SP	925432-86-6P	925432-87-TP	925432-88-8P	925432-89-9P
425412-40-78	425412-41-19	\$25432-\$2-4P	425412-61-5P	

		925432-98-0P	925433-03-0P	925433-08-5P			925433-20-1P		925433 - 30 - 3P	925433-36-9P	925433-41-6P	925433-46-1P			925433-60-9P	925433-65-4P	925433-70-1P	925413-75-6P	925433-80-3P	925433-85-EP	925413-90-5P	925433-95-0P	925434-00-0P	925434 · 05 · 5P	925434-10-2P	925434-15-7P	925434-20-4P	925434-25-97	925434-30-6P	925434-35-1P	925434-40-EP	925434-46-4P	925434-51-1P	925434-56-6P	925434-61-3P	925434-66-EP	925434-71-5P	925434-76-0P
	367363)	925432-97-9P	925433-02-9P	925433-07-4P		925433-15-4P	925433-19-EP	925433-25-6P	925433-29-0P	925433-35-8P	925433-40-5P	925433-45-0P	925433-50-7P	925433-55-2P	925433-59-6P	925433-64-3P	925433-69-8P	925433-74-5P	925433-79-0P	925433-84-7P	925433-89-2P	925433-94-9P	925433-99-4P	925434-04-4P	925434-09-9P	925434-14-6P	925434-19-1P	925434-24-8P	925434-29-3P	925434-34-CP	925434-39-SP	925434-45-3P	925434-50-CP	925434-55-5P	925434-60-2P	925434-65-7P	925434-70-4P	925434-75-9P
	revention of di	925432-96-8P	925433-01-8P	925433-06-32	5433-11-0P	925433-14-3P	925433-18-79	325433-24-5P	925433-28-9P	925433-34-7P	925433-39-2P	925433-44-9P	925433-49-4P	325433-54-1P	925433-58-SP	925433-63-29	925433-68-79	925433-73-4P	925433-78-9P	925433-13-6P	925433-88-1P	925433-93-8P	925433-98-3P	925434-03-3P	925434-01-8P	925434-13-SP	925434-18-0P	925434-23-7P	925434-28-29	925434-33-9P	925434-38-4P	925434-44-2P	925434-49-7P	925434-54-4P	925434-59-59	925434-64-6P	925434-69-1P	925434-74-8P
	treatment and prevention of diseases)	925432-95-7P	925433-00-7P	925433-05-2P	925433-10-5P 525433-11-0P	925433-13-2P	925433-17-6P	925433-23-44	925433-27-8P	925433-32-5P	925433-38-1P	925433-43-8P	925433-48-3P	\$25433-53-0P	925433-57-4P	925433-62-1P	925433-67-6P	925433-72-3P	925433-77-8P	925433-82-5P	925433-87-0P	925433-92-7P	925433-97-2P	925434 · 02 · 2P	925434-07-7P	925434-12-4P	925434-17-9P	925434-22-6P	925434-27-1P	925434-32-8P	925434-37-3P	925434-42-0P	925434-48-67	925434-53-32	925434~58-8P	925434~63-5P	925434-68-02	\$25434-73-7P
	useful in	925432-94-6P	925432-99-1P	925433-04-1P	925433-09-6P	925433-12-1P	925433-16-5P	925433-22-3P	925433-26-7P	925433-31-4P	925433-37-0P	925433-42-7P	925433-47-2P	925433-51-52	925433-56-39	925433-61-OP	925433-66-SP	925433-71-2P	925433-76-7P	925433-81-4P	925433-86-92	925433-91-6P	925433-96-1P	925434-01-12	925434-06-6P	925434-11-3P	925434-16-82	925434-21-SP	925434-26-0P	925434-31-79	925434-36-2P	925434-41-9P	925434-47-5P	925434-52-2P	925434-57-7P	925434-62-4P	925434-67-9P	925434-72-6P
ğ		H																																			٠	

FOR 311275-18-2 HCAPLUS CS Persamidés N-[2-[1H-benzimidasol-2-y])pheny]]-),4,5-trimethoxy- (CA DDEX NAMES)

RB 313376-91-9 NCAPLUS Bearide, N-72-(18-benzimidaso)-2-yl)phenyll-3,5-dinethoxy-NAMES

NH 476631-98-4 HCALUS OB Bengamide, H-(14-bengimidagol-2-yl)phomyll-2,4 HAME)

RN 477491-66-4 HCAFLUS CS Bernande, N-[3-(18-benzinddazol-2-yl)phenyl]-2,4-dim NAME)

	925435-38-7P	925435-43-4P	125435-48-9P	925435-53-6P	125415-58-1P			925435-70-7P	725435-75-2P	925435-80-9P	P25435-85-4P		925435-94-5P	725435-99-0P	125436-04-0P	925436-09-5P	925436-14-2P	P25436-19-7P	925436-26-6P	925436-31-3P	925436-36-8P	925436-41-5P	925436-47-1P	225416-52-EP	925436-58-4P	925436-63-1P	925436-73-3P	925436-86-8P	925436-97-1P	\$25437-07-6P	925437 - 16 - 7P	\$25437-28-1P	925417-35-0P	125437-41-8P	925437-46-3P	925437-51-0P	125437-56-SP	925437-61-2P	925437-66-7P	\$25437-94-1P	254 38 - 74 - GP	:
968)	-	•	-	925415-52-5P 92	925435-57-GP 92			-	925435-74-1P 92	125435-79-6P 92	å	5435-89-87	925415-93-4P 92	925435-98-9P 92	•	•	925436-13-1P 92	-	925436-25-5P 92	125416-10-2P 92	925436-35-7P 92		925436-45-9P 92	925436-51-7P 92	•	-	-	•	•	•	-		•	•	-	925437-50-9P 92	925437-55-4P 92	•	925437-65-6P 92	925437-88-3P 92	25418-69-19 92	
:		•		825435-51-4P 9	925435-56-9P 9	5435-61-69	925435-64-9P 9	•	25435-73-0P 9	125435-78-5P 9	\$25435-83-2P 9	25435-88-7P 925	25435-92-3P 9	125435-97-8P 9	125436-02-8P 9		925436-12-0P 9	-	925436-24-4P 9	25436-29-9P 9	925436-34-6P 9		125436-44-EP 9	125436-50-6P 9	925436-S6-2P 9	•	•	125436-80-2P 9	125436-93-7P 9	-	-	-	•	•	-	925437-49-6P 9	925437-54-3P 9	25437-59-EP 9	125437-64-5P 9	925437-79-29 9	225418-46-6P	
satuent and pre-		•		925435-50-1P	925435-55-8P	925635-60-5P \$254;	925435-63-8P 9	125435-67-2P	125435-72-9P	925435-77-4P	125435-82-1P	125435-87-6P	125415-91-2P	925435-96-7P	925436-01-7P	125436-06-2P	125436-11-9P	-	125436-21-1P	125436-28-8P	125436-33-5P	125436-38-0P	125436-43-7P	125436-49-3P	125436-55-1P	925436-60-8P	125436-66-4P	125436-78-8P	125436-91-5P	125437-01-0P	-	125437-20-3P	125437-12-79	125437-37-29	125437-43-08	125437-41-SP	125437-53-2P	125437-58-7P	325437-63-4P	925437-75-8P	125418-11-7P	925439-81-9P
		-		925435-49-0P	925435-54-7P	925435-59-2P 92	\$25435-62-7P	925435-66-1P	925435-71-8P	925435-76-3P	925435-81-0P	925435-86-5P	925435-90-1P	925435-95-6P	925436-00-6P	925436-05-1P	925436-10-8P	925436-15-3P	925436-20-0P	925436-27-7P	925436-32-4P	925436-37-9P	925436-42-6P	925436-48-2P	925436-53-9P	925436-59-5P	925436-65-1P	925436-76-6P	925436-89-1P	925436-99-3P	925437-09-82	925437-18-9P	925437-30-SP	925437-36-1P	925437-42-9P	925437-47-42	925437-52-1P	925437-57-6P	925437-62-3P	925437-68-92	925418-01-19	925430-79-50
	Ħ																																									

29 717828-13-2 NCAPLOS OF Percentide, J.4-dimethoxy-N-(3-(6-methyl-1H-benzimidazol-2-yl)phenyl)- (CA TOTEX NUME)

EN 920814-15-9 HCAPLES
CH Bengerasererande, N-[2-(14-benzimtdagol-2-y1)phanyl]-1,4-dimerbox
FUESK NAVE]

RN 925432-19-5 HCAPLUS CN Benzamide, N-12-(1H-benzimidazol-2-yl)phanyl]-3,4-disetboxy- (CA DORK NAME)

925432-20-8 HCAPLUS Benzenssulfonamids, N-[2-(1H-benzimidazol-2-yl)phenyl]-: INDEX MAME)

93444-00-49 935444-01-89 935444-03-49
Li Die, Franzandolphola Destroyol, 9000 (Spatial of Proparation);
WO (Examples of Proparation Outs) (Open (Spatial of Proparation Outs));

| Comparation of Spatial Open (Spatial of Proparation Open (Spatial of Proparation Outs) (Spatial of Proparation Open (Spatial of Propara

1917 17 Section of the section of th

EN 101141-65-3 RCMFLIS CN Bernarde, B-[4-(1H-bernalmidaxol-2-y])pheny]]-1,4,5-trimethoxy-HANCE.


ES 105154-06-1 HCAPLUS
Nemarande, N-(3-(1H-bensimidazol-2-yl)phenyl]-2,6-dinethoxy- (CA INDEX
NAME)

B9 925432-18-4 HCAPLUS CF Urea, N·[2-(1H-benzimidazol-2-yl)phemyl]-N-methyl-N-phemyl- (CA INDEX NAME)

29 91543)-10-9 ECATLES OF Personide, 1-8-(4-(1H-benzinidazol-2-yl)-2-pyridinyl)-3,4,5-trimethoxy- (CA DUDE volt)



May 16, 2007 1-Piperszinetarbosylic scid, 4-[(4-[[[2-(H-benzimadazol-2-yl)phenyl Jamiol carbonyl)-2-merbosyphenyl]methyll-, 1,1-dinsthylethyl ser [ch. 1005x 1404]



925435-62-7 HCAFLUS Benzamide, #-[2-(1R-benzimidazol-2-yl)phemyl]-: piperazinylmethyl)- (CA INDEX NAME)





925418-79-5 KCAPLUS Benzamide, N-(6-(1H-benzimidazol-2-yl)-INDEX NAME)



RM 925413-53-0 RCAPLUS CN Benzemide, 2.4-dimethoxy-N-[2-(1-methyl-1H INDEX NAME)



May 16, 2007

THEME ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT :171908 HCAPLUS Full-rext 274369 REFERENCE COUNT:

n of exazolopyridine derivatives as sirtuin DIVENTOR(S):

PATENT ASSIGNEE(S): SOURCE: DOCUMENT TYPE:

May 16, 2007

RN 925435-21-B HCAPLUS CN Benzamide, N-[2-(1H-benzimidazol-2-yl) INTEX NAME)

925415-22-9 ECAFLUS 2-Quinoxalinecarboxamide, W. HAME)



925435-61-6 HCAPLUS

839692-36-3P 672330-71-1P 34291-07-5P 153343-62-5P 248583-16-6P 303141-65-JP 112795-64-5P 312742-54-4P t

OTHER SOURCE(S):

CONT 10 6001	96 - 37	-29-9P	-35-79	40-47	45-92	-50-6P			-61-4P	46-99·	.75-0P	-80-7P	45-2P	-90-9P	45-42	-00-4P	-05-9P	.10-6P	15-19		25-3P	30-01	35-5P		49-11	49-15	4-15	59-1P	40.00	24-35	79-17	-04-4E	46-68					din		98 - 0P	03-02	45-80			20-17	
	199319-08-3P	908569-29-92		908569-40-47	908569-45-99	908569-50-6P				925431-66-99							925432-05-9P	925432-10-6P	925412-15-19		925432-25-3P	925432-30-0P	9254 32~35-5P		925432-44-62	925432-49-19	925432 - 54 - 82	925632-59-39				925432-84-42	925432-89-99		ation);			go as eart	î	925432-98-0P	925433-03-0P	925433-08-5P			925433-20-1P	
	879576-37-1P	908569-28-82	908569-34-6P	908569-19-1P	908569-44-BP	908569-49-38	908569-54-0P	923441-68-39	925431-60-3P	925431-65-EP	925431-74-9P	925431-79-42	925431-84-1P	925431-89-6P	925431-94-38	925431-99-EP	925432-04-EP	925432-09-3P	925432-14-0P	3437-27-89	925432-24-2P	925432-29-78	925432-34-4P	925432-39-9P	925432-43-5P	45432-48-05	925432-53-79	925432-58-28	26.50.75.67.6	225432-01-12	925432-78-67	925432-83-39	925432-88-82	925432-93-5P	nthetic prepar	dy); PREP		ines and analo	ntion of disease	925432-97-9P	925433-02-9P	925433-07-4P		925433-15-4P	925433-19-8P	47.24.11.76.45
0/356 432	\$63589-52-0P	908569-27-7P	908569-33-SP	908569-38-0P	908569-43-7P	908569-48-2P	908569-53-9P	922456-95-9P	925431-59-0P	925431-64-7P	925431-72-7P	925431-78-3P	925431-63-0P	925431-88-5P	925431-93-2P	925431-98-72	925432-03-7P	925432-08-2P	925432-13-9P	\$254.17-19-5P \$254.15-20-8P	925432-23-1P	925412-28-6P	925432-33-3P	E5432-38-4P	925432-42-48	925432-47-9P	925432-52-6P	925432-57-1P	20.70.70.676	925412-67-35	925432-77-SP	925432-82-2P	925432-87-7P	925432-92-4P	TIEN SPN (Sy	Biological stu-		d exazolopyrid	ment and preve	925432-96-8P	925433-01-8P	925433-06-3P	433-11-09	925433-14-3P	925433-18-7P	435133 21 64
	863589-44-07	901569-25-5P	908569-32-48	908569-37-92	901569-42-68	908569-47-1P	904569-52-8P	322456-90-4P	925431-58-9P	925431-63-6P	925431-70-5P	925431-77-2P	925431-82-98	925431-87-4P	925431-92-1P	925431-97-62	925432-02-6P	925432-07-1P			925432-22-0P	925432-27-SP		-	925432-41-1P	925432-46-8P	925412-51-59	925432-56-02	21-10-25-676	925432-00-21	925432-76-42	925432-81-1P	925432-86-69	925432-91-3P	ascological society); SPN (Synthetic preparation);	(Therapentio mee); BIOL (Biological study); PREP	(Preparation); USES (Uses)	(preparation of substituted exazolopyridines and analogs as sirtuin	useful in treatment and prevention of diseases)	925432-95-72	925433-00-72	925433-05-2P	925433-10-9P 925433-11-0P	925433-13-2P	۵.	
	063519-21-0P	908569-23-32	908569-31-32	908569-36-BP	908569-41-5P	908569-46-09	908569-51-7P	\$20814-15-59	925223-55-8P	925431-62-5P	925431-68-1P	925431-76-1P	925431-81-8P	925433-86-3P	925431-91-0P	925431-96-52	925432-01-5P	925432-06-0P	925432-11-7P	925412-16-2P	925432-21-9P	925432-26-4P	925432-31-1P	925432-36-6P	925432-40-2P	925432-45-78	925432-50-4P	925432-55-92	45-09-77-674	925412-65-12	925432-75-38	925432-80-09	925432-65-5P	925432-90-2P	RL: PAC (Phase	THU (Thermond	(Preparation)	(preparat)	modulators	925432-94-6P	925432-99-1P	925433-04-1P	925433-09-6P	N25433-12-1P	925433-16-5P	
																																								Ľ						

R 195158-08-1 ECAFAUS GW Benzemide, N-(3-(1H-benzimadazol-2-yl)phemyl)-2 RMS

RR 111275-18-2 HCAPAUS ON Bernamide, N-(2-(1R-benzimidazol-2-y3), NAME)

EN 11176-91-9 HCAPLUS ON Benzamide, N-[2-(IH-benzimidazo] NAME)

EM 477493-06-4 HCMFLUS CM Benzemide, N-[3-(1H-benzimidazol-2-y]) NAME)

The state of the s

EN 920914-15-9 HCAPLUS CN Berzenacetamide, N-[2-(1R-benzimidatol-2-yl)phe INEEX NAGE

EM 925432-20-W HCAPLUS CM Benzensehlfonsmide, N-{2-(lH-ben INDEX NAME)

RN 925432-38-8 HCAPLUS ON UNes, N'-(2-(1H-benzimidaze NAME)

1.Piperezinecarborylic ecid. 4-[[4-[[1]-]]h-bezindazol-2-yliphorylianio]eshebarylia-2-setboryphorylis-1.1.disetbyletbyl erer (A. Fuzz Now?)

925418-79-5 HCAPLUS Benzamide B-[6-(1H-benzimidazol-3-yl) DCGEX NAME)

925413-56-7 HCAPUS Berrande, 1,44,5-trimethoxy-B-[2-(1-methyl-1H-benzimidazol-2-yl)phenyl]-(CA DORE RANG)

925431-51-8 HCAPLUS Benzamide, 3.4-dimethoxy-N-[2-(1-methy]-1H-benz INDEX MAME)

EM 925433-53-0 HCAPLUS CM Benzamide, 2,4-dimethoxy-N-[2-(1-methyl-1R INDEX NAME)

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAN SPERENCE COUNT:

and STR control of the control of th DRVENTOR (S):

DOCIMENT TYPE:
LANGUAGE:
PAMILY ACC. NUN. COUNT:
PATENT DIFORMATION: PATENT ASSIGNEE(S): SOURCE:

RN 925415-21-9 HCAPLUS CN Bentamide, N-[2-(1H-benzimidazol-2-yl)-INEX NAG)

925435-22-9 HCAPLUS 2-Quinoxalinecarboxamide, N-[2-(1H-ben: NAME)

925415-60-5 HCAPLUS 2-Quinolinecarboxamide, NAME)

925435-61-6 HCMPLUS

The still compdet of TRES, Date of R. We are molabilities appear; DES = N or combilities again; DES = N or combilities again; DES = N or combined against the still composities against the still composities and their manipulation that manipulation and their manipulation amongstill or services and their manipulation amongstill or services and their manipulation amongstill or services and their manipulation and the second to composite a straight manipulation and the second and the special and their manipulation and the second in combination with another that manipulation and their manipulation and the second to composite and their manipulation and their manipulation and their manipulation and their manipulation and the second to combination with another manipulation and their manipulation and the second and the second and their manipulation and the second and the

threakonytopeanie, drug-induced, preparation of disclosopyridines and spalogs as sirtuin modulators useful nt and prevention of diseases) epsenia, drug-induced, preparation of substituted didnes and analogs as sirtuin modulators useful in tion of diseases)

OTHER SOURCE(S): GI

May 10, 2(U)	908569-29-92	908569-15-72	26-54-65-00	908563-50-6P			925431-61-4P	925431-66-9P	125431-75-0P	925431-80-7P	125431-85-2P	925431-90-9P	125431-95-4P	925432-00-4P	825432-05-9P	925432-10-6P	925432-15-1P	:	25432-25-3F	40-01-71-675	37-55-75	325432-44-6P	925432-49-1P	925432-54-8P	925432-59-3P	125412-64-0P	25432-69-5P	20170-10170	925432-84-4P	925432 - 89 - 9P					alreain	925432-98-0P	925433-03-0P	925433-08-5P		91-00-11-36-18		925433-30-3P	925411-16-9P	925433-41-6P	925433-46-1P		\$25433-60-9P	125433-65-4P	#25433-70-1P	925433-75-6P	925433-80-39	413.13.15.15.	925433-95-0P	
	•	908569-34-67				923441-68-3P	925431-60-3P 925		•	•	•	925431-89-6P 925	•	925431-99-8P 925	-	•	60-			925432-29-16 92:		٠.		925432-53-79 929		•	925432-68-4P 92:			-		(wity); SPN (Synthetic preparation);	n): PREP			97.99		925433-07-4P 92:		025411-10-02		<u>.</u>	-			925411.55.20	4	-	•	•	925433-79-0P 92:		925433-89-2P 92:	
107.88.CM	908569-27-79	904569-13-52	908569-43-72	908569-48-2P	908569-53-9P	922456 - 95 - 9P	925431-59-0P	925431-64-79	925431-72-7P	925431-78-32	925431-83-0P	925431-88-5P	925431-93-2P	925431-98-7P	925432-03-7P	925432-08-2P	925432-13-9P	925432-19-5P 925432-20-6P	925432-23-12	925432-28-68		ڇ	925432-47-9P	925432-52-6P	925432-57-1P	925432-62-8P	925432-67-3P	40.000	925432-82-2P	925432-07-79	925432-92-4P		(Therapeutic use); BIOL (Biological study); PREP		substituted imidatopyridines and analogs	925432-96-8P	925433-01-8P	925433-06-3P	75433-12-29	075411-10-70		۵,	925433-34-72	925433-39-2P		975413.54.18 97	۵,	925433-63-2P	925433-68-7P	925431-73-4P	925433-78-98	A	925433-88-1P 925433-93-RP	
	-	908569-32-47			-	922456-90-42	925431-58-9P	-	•	925431-77-2P		925431-17-4P	925431-92-1P	925431-97-6P	-		-			925412-27-58				925412-51-5P		-	. 925432-66-2P			-		RL: PAC (Pharmacological act	utio use); BIOL		ton of subscritte	925433	925433-00-7P		Š,	47-51-55 676	2		•			#15/83-63-000			925433-67-6P	-	-		925433-87-02	
	908569-23-3P	908569-31-38	908569-41-5P	904569-46-02	908569-51-72	820814-15-8P	925223-55-8P	925431-62-SP	925431-68-1P	925431-76-1P	925431-81-8P	925431-B6-3P	\$25431-91-0P	\$25431-96-5P	925432-01-5P	925432-06-0P	925432-11-78	925432-16-2P	925432-21-99	925432-26-4P	425417.16.60	925432-40-2P	925432-45-72	925432 - 50-4P	925432-55-9P	925432-60-6P	925432-65-12	40-0/-75-5574	425412-13-16 425412-80-0P	925432-15-5P	925432-90-2P	RL: PAC (Plan	TRU (Therape	(Preparation	(preparation of s	TT 925412-94-6P	-	\$25433-04-17	925433-09-6P	323633-12-16	925433-22-3P	925433-26-7P	925433-31-4P	925433-37-0P	925433-42-78	27-43-47-676	425411-56-12	925433-61-0P	925433-66-5P	925433-71-2P	925433-76-79	923433-61-62	925433-86-97	

NO 19539-08-1 ROMFUS ON Bearmide, N-[1-(1H-bearimidaro)-2-yl)phemyl]-2,f-dimetho IOPE)

RF 111275-18-2 RCAFLUS CF Benzamide, F-[2-(1H-benzimidazol-2-yl)phenyl]-3,4,5 RAES)

Ed 111176-91-9 HCAPUS CM Benzemide, N-{2-(1M-benzimida NANE)

The state of the s

RN 477483-06-4 HCAPLIN CN Benzamide, N-[3-(IH-benzimidazol-2-yl)phenyl]-2. NAVE)

EN 920814-15-9 HGAFLUS CH Benzenearetanide, F-[2-(1R-benzimidazol-2-yl)phenyl]-3, DUEX NAG)

925432-19-5 HCAFLUS Benzamide, H-[2-[1H-benzimidazo]-2-yl]phenyl]-3 NAWG)

DS 925412-18-8 HCAPLUS CS Ores, N'-(2-(18-benzimidazol-2-) NAME)

o de la companya de l

10/538 252 May 16, 2007

91541)-11-0 HCMULS Bernanda, 1-7 (-(1H:bennimidatol-2-yl)-2-pyridiny]]-3.4-dimethoxy- (CA DUES WWE)

RN 925433-12-1 HCAPLUS





EN 928415-62-7 HCAPLIS

CN Benzanide, N-{2-(1H-benzinidazol-2-yl)pbenyl}-1-methoxy-piperazinylmethyl)- (CA DUEX NAME)



EN 935435-89-9 HCAPLUS

CH Benzemide, N-(2-(1H-benzimidzol-2-yl)phemyl]-1-methoxy-pyrrolidinylmethyl)- (CA DUZK NAKE)



RN 92441-19-5 KCAPLIS CN Paracide, N-(6-(1H-bensimidasol-2-yl)-2-pyridinyl]-2,3,4-trimethoxy- (CA DUZA hWG)

93431-50-7 HOMFLES
Pentandide 1.4.5-trinethoxy-N-(2-(1-methyl-1H-bentifuldatol-2-yl)phenyl](Ca. DUDE MAG)

20 929431-51-2 HOAPLES CH Bernarde, 3,4-diswtbory-N-[2-(1-sethyl-1H-benzimidazol-7-yl)phen DUGEN HAME)



ns 92441-81-0 RCMFLIS CM Perizadio 2.4-dismchoxy-N-(2-(1-sethyl-1H-benzinidezol-2-yl)phenyl)-INTEX NWE)



Ed. 925435-17-2 HCAPLUS Gr. Bertamide, Ft. (2.14-bert inidazo1-2-yl) pheny]]-3-methoxy-4-(4morpholiuy)aethyl)- (Ch. JUDIX NMCI) 38.252 May 16, 2007

RETRIBUCE COMPT: 2 THURS ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE TO THE RE FORMAL

ACCESTOR MACHINE TO THE MACHINE TO THE MACHINE TO THE MACHINE TO THE MACHINE T

SOURCE: SITTIE PARENTS
SOURCE: PCT Int. Appl.
CODEN: PIXOD
CODEN: PIXOD

DOCUMENT TYPE: PAtent LANGUAGE: PAGIL: Englis: FAMILY ACC. NUM. COUNT: 8 PATENT IMPORMATION:

| Mariet 100. | Marie 100 | Ma

MARPAT 146:274349

OTHER SOURCE (8): GI

EP 15415-21-8 HOJELES OF Bennamids. | F-[2-114-ben14m]dayol-2-yl] -4-methylphenyl]-3,4-dimethoxy-DESE MARE)

ED 925435-22-9 ROALUS OH 2-QUIDOXALLEGEAEDXXARIĞA, N-[2-(1H-benzinidazol-2-yl)phenyl]- (CA IDTR NAME)

| 924.15-60-5 HCAFLES | 2-0.1inol.inecarboxamide, 9-[2-(IR-benzimidazol.-2-yl]phenyl]- (CA DUB | RAFE)

925435-61-6 HCAPLUS

The state of the s

An The title comput in [17-11s w. M. Ord or crit to therein 200 or crit to the computation of the computation of the critical professor and consideration of the critical professor and considerated association or bicyclic floatenessy; this provises and that sanious statistics associated or bicyclic floatenessy; this provises and that sanious of a call, and treating and/or preventing a vide warriety of diseases and discovers including the lifessor and discovers including configurative diseases; candiovamental and cases, calcious and calcium configuration frome, and/or and and calcium configuration frome, and/or and/or and and and and a proposed in a military suppression of a calcium configuration of the configuratio

combination with importer thereperated agents.

If it is the compounds there is a section compound.

If it is a section compound the compounds the compound the c

(thereborgerates), dury-induced; properation of benochiaches and that can experience of diseases) the second secon

		10,530,636		100 TO 10
689756-12-5P	694469-31-3P	708287-71-2P	708995-11-3P	717120-17-7P
71.7228-13-2P	724740-48-1P	831249-33-3P	832106 - 98 - 6P	
832684-02-3P	933429-29-1P	#35890-43-2P	835897-82-0P	#19692-36-3P
862811-69-69	\$61020-18-2P	863589-18-8P	863589-21-3P	\$63589-23-5P
861589-28-0P	863589-44-02	863589-52-0P	879576-37-1P	899389-08-3P
908569-23-3P	901569-25-5P	908569-27-7P	901569-28-1P	908569-29-9P
908569-31-32	908569-32-4P	908569-33-5P	401569-34-62	908569-35-79
908569-36-82	908569-37-92	908569-38-0P	901569-39-3P	908569-40-4P
908569-41-SP	901569-42-6P	908569-43-7P	901569-44-BP	908569-45-92
908569-46-02	901569-47-1P	908569-48-2P	908569-49-3P	908569-50-62
908569-51-79	901569-52-RP	908569-53-9P	401569-54-0P	
920814-15-92	922456 - 90-4P	922456-95-9P	923441-68-1P	
925223-55-8P	925411-58-9P	925431-59-0P	925431-60-3P	925431-61-4P
925433-42-5P	925433-63-6P	925431-64-7P	925431-65-0P	925431-66-9P
925431-68-1P	925431-70-SP	925431-72-7P	925431-74-9P	925431-75-0P
925431-76-1P	925431-77-2P	925431-78-3P	925431-79-4P	925431-80-7P
925431-81-8P	925431-82-9P	925431-83-0P	925431-84-1P	925431-85-2P
925431-86-3P	925431-87-4P	925431-88-5P	925431-89-6P	925431-90-9P
925431-91-0P	925431-92-1P	925431-93-2P	925431-94-3P	925431-95-4P
925431-96-5P	925431-97-6P	925431-98-7P	925431-99-0P	925432-00-4P
925432-01-5P	925412-02-6P	925412-03-7P	925432-04-8P	925432-05-9P
925432-06-0P	925412-07-1P	925412-08-2P	925432-09-3P	925432-10-6P
925432-11-7P	925432-12-8P	925432-13-9P	925432-14-0P	925432-15-1P
925432-16-2P	925432-18-4P	ES432-19-EP 9254	5432-20-8P	
925432-21-9P	925432-22-0P	925432-23-19	\$25432-24-2P	925432-25-3P
925432-26-4P	925432-27-5P	925433-28-6P	925432-29-7P	925432-30-0P
925432-31-1P	925432-32-2P	925432-33-3P	925432-34-49	925432-35-5P
. 925432-36-6P	925432-37-7P	\$25432-39-8P	325432-39-9P	
925432-40-2P	925432-41-3P	925432-42-4P	925432-43-59	925432-44-6P
925432-45-79	925432-46-8P	925432-47-9P	925432-48-0P	925432-49-1P
925432-50-4P	925432 - 51 - 5P	925432-52-6P	925412-53-7P	925432-54-EP
9254 12 - 55 - 9P	925432-56-0P	925432-57-1P	925432-58-2P	925432-59-3P
925432-60-6P	925432-61-7P	925432-62-8P	925432-63-9P	925432-64-0P
925432-65-1P	925432-66-2P	925432-67-3P	925432-68-6P	925432-69-5P
925432-70-8P	925432-71-9P	925432-72-0P	925432-73-1P	925432-74-2P
\$25432-75-3P	925432-76-4P	925432-77-5P	925432-78-6P	925432-79-7P
925432-80-0P	925432-81-1P	925432-82-2P	925432-83-39	925432-84-4P
925432-85-59	925432-16-6P	925432-87-79	925432-BB-8P	925432-89-9P
925432-90-2P	925432-91-3P		925432-93-5P	
EL: PAC (Phase	PAC (Pharmacological activity); SPM		(Synchetic preparation);	:(m);
Thy (Therapett	(Therapectic use); BIOL (Biological	(Biological stu	study); FREP	

925433-20-1P 925433-30-3P 925433-36-9P 925433-41-6P 925433-46-1P

925433-60-99 925433-65-4P 925433-70-1P

.EN 305354-04-1 HCAPLUS CN Bentamide, N-[3-(1H-benzimidazol-2-y]) NAME)

RN 313275-18-2 HCAPLUS CN Benxamide, N-[2-(1H-benximidasol-2-yl)phemyl)-RAWE)

113376-91-9 HCAFLUS Benzamide, N-[2-(1H-benz) NAME)

RN 477433-66-4 HCMFLIS GN Berzzenijes, N-{3-(1K-benzinidazol-2-yl);phenyl]-2. ROGE)


DH 117828-13-2 HCMFLUS CD Bennamide, 3,4-dimethoxy-H-[3-(6-methy]-1H-ben DUDEX NAME)

EM 920814-15-9 RCAPLUS CM Benzeneacetamide, N·[2-(1M-benzimida INTEX NAME)

RF 92512-19-5 HOLPUS GR Benzandés, B- (2-(Ht-benzindészol.-2-yl)phenylj-3,4-NWG)

RM 925432-20-8 HCAPLUS CH Benzensulfonamide, N-[2-(1) DHEK MAME)

EN 925432-38-8 HCAFLUS CN Urea, N'-[2-(1H-benz) NAME)



EN 925413-12-1 HCAPLUS CN Benzamide, N-{6-(IH-benzimida NANE)



May 16, 2007

925435-60-5 HCAPLUS 2-Onimolinecarboxamide, F-[2-(1H-benzimidazol-2-yl)phenyl]-Maser



ED 925435-61-6 HORPIUS ON 1-Piperazinachosylte acid, 4-[[4-[[]2-[III-benzinidazo]-2-yl)phenyll-acino[carbonyl]-2-marboxyphenyl]methyl]-, 1,1-dimethylethyl ester (GA DOGE NAMO)



935435-62-7 HCAPLUS Benzamide, N-[2-(IH-benzimidezol-2-yl)pbeny piperazinylmethyl) - (CA INDEX NAME)



925415-89-8 HCAPLUS
Benramide, N-[2-(1H-benrimidazol-2-yl)phenyl]-)
pyrrolidinylmethyl)- (CA ENDER NAME)

EM 925433-50-7 RCAFLUS CN Benzamide, 3.4.5-trimethoxy-N-(CA DNDEX NAME)



DN 925433-51-8 HCAPLES CN Benzamide, 3.4-dimethoxy-N-[2-(1-methy]-1N-benz INDEX NAME)



NN 925418-79-5 HCAPLUS CN Benzamide, N-[6-(1H-benz: INDEX NAME)




EFERENCE COURT.

A ANGELE ALOR 23	14 AGASTAL VOT 23 NUMBER OF STATE OF STATE FOR THE FORM
LESSION BUNGER:	CONTITUTE BOWLETE CONTITUE
COMPAT MARKER:	146:274367
ITLE:	Preparation of imidazo[2,1-b]thiazole derivatives as
	sirtuin modulators
INDIANOR (5):	Munes, Joseph J.; Milne, Jill; Bemis, Jean; Xie,
	Roger; Vu. Chi B.; Ng, Put Yee; Disch, Jeremy S.
ATENT ASSIGNEE (S):	Sirtris Pharmaceuticals, Inc., USA
CARCE:	PCT Int. Appl., Stipp.
	COMPAN BIXATIO

1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

RN 925415-17-2 HCAPLUS CN Benzamide, N-[2-(1H-benzimidazol-2-yl)phenyl] morpholinylmethyl)- (CA IMER NAME)



EN 925435-21-W HCAPLES CN Benzamide, N-[2-(1H-benzi INCEX NAME)



EM 925435-22-9 HCAPLUS CM 2-Quinoxalinecarboxamide, HAME)



A. 2007215 US 2006-45929 A. 2007215 US 2006-45991 A. 2007215 US 2006-45991 O. A. 2007215 US 2006-49991 O. US 2006-79919 OTHER SOURCE (S): GI

ä

eda, drug-induced; preparation of substituted thistoles and analogs as sirtuin modulators useful in prevention of diseases)

248583-16-6P	,	47.	•		- 41.507-40-1P		-7F 443910-77-4F	-1P 672130-71-1P			-OP #19692-36-3P	-	-1P 899389-08-3P	-4P 908569-29-9P			-47 908569-45-9P	-3P 908569-50-6P	do-	-JP		•	•	•	-	•			-	•	-OP 925432-15-1P		-2F 925432-25-3F			-SP 925432-44-6P	-		•	-	-	-	-	•	-07 925432-19-92		paration);		
153343-62-59			=		F 404831-82-9P		443756-30-79	٠.		_	-	P 61519-21-3P	Q 479576-37-1P	P 908569-28-8P	•	•	•	-	•	•	•	•	٠	•		•	•	•	-	-	P 925432-14-0P	Ň	72-22-24-27		2	P 925432-43-5P	•	•	•	•	-	•	-	•		45-74-753674	(Synthetic preparation); stucki: perp	· · · · · · · · · · · · · · · · · · ·	
134291-07-SP	4	312595-64-52	7		381175-26-4P		443754-20-5P			_	_	_	863589-52-0P	908569-27-7P	•	•	908569-43-7P	•	-	•	-	•	•	•	•	•	-	-	-	-			925412-23-12	-	5	925432-42-4P	•	•	•	•	•	-	•	•					
70553-45-6P	234532-08-38	303256-05-59	3:32/2-96-67	310995-99-67	180573-48-89	77.06.66066	443755-92-88	550100-04-4P	694469-33-39	724740-48-18	833429-29-1P	\$63020-18-2P	863589-44-0P	908569-25-52	908569-32-4P	908569-37-9P	908569-42-6P	908569-47-12	908569-52-EP	922456-90-4P	925431-58-9P	925431-63-6P	925431-70-5P	925431-77-2P	925433-82-9P	925431-87-4P	925431-92-1P	925431-97-6P	925432-02-6P	925432-07-1P	925432-12-8P	925432-18-42	10-22-25-05	925432-32-2P	925432-37-78	925432-41-3P	925432-46-8P	925432-51-5P	925432-56-0P	925432-61-7P	925432-66-24	925412-71-9P	925432-76-4P	925432-81-1P	925432-86-67	45-74-75-574	Lis P.M. (Makemanical activity); SPN 1997; SPN	(Preparation): (ISES (Thes)	
3980-14-1P	294874-78-52	102328-04-1P	31.273-18-21	20-01-111-10-05	154121-14-92	AT . 07 - COATE	442522-39-68	\$41685-09-6P	689756-12-5P	717828-13-25	832684-02-3P	862811-69-6P	863519-21-09	908569-23-3P	908569-31-38	908569-36-8P	908569-41-5P	908569-46-67	908569-51-7P	920814-15-99	925223 - 55 - 6 P	925431-62-SP	925431-68-1P	925431-76-1P	925431-81-8P	925431-86-3P	925431-91-0P	925431-96-5P	925432-01-SP	925432-06-0P	925432-11-78	925432-16-28	923412-21-94	925432-31-19	925432-36-6P	925432-40-2P	925432-45-7P	925432-50-4P	925432-55-9P	925432-60-6P	925432-65-1P	925432-70-8P	925432-75-3P	925432-80-0P	925432-85-54	77-06-75-67	THE PART AND	(Prenaration)	
Ħ																																																	

| Preparation | (1975) | (1944) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947) | (1947

*** The state of t

pr 19344-65-3 (CAPULE) CF Petrancide, Pr(4-(19-benzinackarol-2-yl)phenyl]-3,4,5-trimethoxy- (CA DDD MANE)

DV 18551-04-1 KCAPAJS OF Percandide, N-(1-(1H-benzimidazol-2-yl)phenyl]-2,6-dimethony- (CA INDI NAWE)

Service of the servic

D 111775-18-2 HGDFLDS OF Benzumide, No {2 · (18-benzimidazol-2-yl)phenyl}-3.4,5-trimethoxy- (CA.DUEK NAGE)

ES 111176-91-9 RCLPLUS CH Benzunide, N-[2-(1R-benzimidazol-2-yl]pheny])-1,5-dimethoxy- (CA INGEX NAME)

| (Preparation | unas principal | preparation | preparatio

pp cfs13-91-4 [GDPLDS]

GPRIMAGIds. P-[4-(1R-bernimidasci-2-yl)phemyl]-3,4-dimethoxyMANE)

The state of the s

DF 47431-06-4 HORLIS OF Bernardes, B-[1-(14-bern:1mids:00]-2-y])pheny]]-2,4-disstboxy- (CA BACK)

El 11782 - 13 - 2 HOUPUS On Bernande, 1,4-diswibory-M-(3-(4-methy)-1H-benzimachsol-2-yl)pbenyl)- (CA TERES MOS)

PARTIE 15-9 HCAPLING THE RESERVED BY (2-(18-bent insidazo)-2-yl) phenyl]-1, 4-dimethoxy- (CA THE RESERVED BY (2-(18-bent insidazo)-2-yl) phenyl]-1, 4-dimethoxy- (CA

		10/238 257		May 16, 21
925435-90-1P	925435-91-2P	925435-92-38	925435-93-4P	925415-94-5P
925415-95-6P	925435-96-7P	925435-97-8P	925435-90-9P	925435-99-0P
 925436-00-6P	925436-01-7P	925436-02-11	925436-03-9P	925436-04-0P
925436-05-1P	925436-06-2P	925436-07-32	925436-08-4P	925436-09-5P
925436-10-8P	925436-11-9P	925436-12-0P	925436-13-1P	925436-14-2P
925436-15-3P	925436-16-4P	925436-17-5P	925436-18-6P	925416-19-7P
925436-20-0P	925436-21-12	925436-24-42	925436-25-5P	925436-26-6P
925436-27-7P	925436 - 28 - BP	925436-29-9P	925416-30-2P	925436-31-32
925436-32-4P	925436-33-SP	925436-34-6P	925436-35-79	925416-16-89
925436-37-9P	925436-38-CP	925436-39-12	925436-40-4P	925436-41-5P
925436-42-6P	925436-43-79	925436-44-8P	925436-45-9P	925436-47-1P
925436-48-2P	925436-49-3P	925436-50-6P	925436-51-7P	925436-52-8P
925436-53-9P	925436-55-12	925436-56-2P	925436-57-39	925436 - 58 - 4P
925436-59-5P	925436-60-8P	925436-61-9P	925436-62-0P	925436-63-1P
925436-65-3P	925436-66-42	925436-69-7P	925436-71-12	925436-73-3P
925436-76-6P	925436-78-8P	925436-80-28	925436-83-SP	925436-86-89
925436-89-1P	925436-91-5P	925436-93-72	925436-95-9P	925436-97-1P
925436 - 99 - 1P	\$25437-01-0P	925437-03-2P	925437-05-4P	925437-07-6P
925437-09-EP	925437-10-1P	925437-12-3P	925437-14-5P	925437-16-7P
925437-18-9P	925437-20-3P	925437-22-5P	925437-26-9P	925437-28-1P
925437-30-SP	925437-32-72	925437-33-8P	925437-34-92	925437-35-0P
925437-36-1P	925437-37-2P	925437-38-3P	925437-39-4P	925437-41-8P
925437-42-9P	925437-43-0P	925437-44-1P	925437-45-2P	925437-46-3P
925437-47-4P	925437-48-59	925437-49-6P	925437-50-9P	925437-51-0P
925437-52-1P	925437-51-2P	925437-54-3P	925437-55-4P	925437-56-5P
925437-57-6P	925437-58-7P	925437-59-8P	925437-60-12	925437-61-2P
925437-62-3P	925437-63-4P	925437-64-SP	925437-65-68	925437-66-7P
925417-68-9P	925437-75-82	925437-79-2P	925437-88-32	925417-94-1P
925438-01-1P	925438-13-7P	925438-46-6P	925438-69-3P	925438-74-0P
\$25438-79-5P	325438-81-9P	925443-98-7P	925443-99-BP	
	03 to . 0 . 0 . 0 . 0	*******		

The first termination is 1500 (180.0); FRD
(Frequencia west, 1500 (180.0); FRD
(Frequencia west, 1500 (180.0); FRD
(Frequencia west, 1500 (180.0); FRD
(Frequencia of washings we sixtu

13122-1-15 13134-1-15 13141-1-15 13131-1-15

(preparation of substituted haddso(1,1-b)thatoles and analogs as struit modalators useful in treatment and prevention of diseases) 3 24474-71-5 NCACLUS Meanmaids, N-(4-(in-benzimidaso)-2-y1)phenyll-1,4-disetbony- (CA DROEX NAVE)

2,8820)

pr 92412-13-5 HCAFUS O Bessenick, P-[2-(14-bessinstated-2-y])phenyl]-1,4-dimethoxy- (CA DUDS LWR2)

ES 93432-20-6 HOAFLUS ON bennesselfonanide, N-(2-(1H-benninidatol-2-yl)phenyl)-1,4-dimet DIES NAG)

EN 15412-18-8 HCAPLUS GW TOSA N'-(2-(1H-benzinidazol-2-yl)phenyl]-N-methyl-N-phenyl- (CA DEN NAME)

UN \$25433-10-9 HCAPLUS

10/538,252

EN 925433-11-0 HCAPLUS CN Benzamide, N-(6-(1H-benz INDEX NAME)




RD 925433-12-1 HCAPLUS CN Bertzamide, N-(6-(1H-benzimidazol-2-y])-2-pyridinyl] MANES



925435-60-5 HCAPLUS 2-Quinolinecarboxamide, NAME)



925415-61-6 HCMFLDS 1-Piptoralizationalization acid, 4-[[4-[[]2-(1H-bensimidaco]-2-91)phonylladicolestbooyll-2-methoxyphenyllanthyll-, 1,1-dimethylethyl ester (CA. DODEK NAME)



925415-62-7 HCMFLUS
Benzamide, N-[2-(1H-benzimidazol-2-yl)phemyl]piperazinylmethyl)- (CA IMBE MANE)



925435-99-8 HCANLUS Benzamide, N-[2-(1H-benzimidazol-2-yl)phenyl]-3-m pyrrolidinylmethyl)- (CA INDEX NAME)

EM 925433-50-7 HCAPLUS
CN Benzamide, 3,4,5-trimethoxy-1
(CA DEDEX NAME)



925413-51-W HCAFLUS Berzamide, 3,4-dimethoxy-N-[2-(1-methy]-DUEX WAG)



925433-53-0 HCAPLUS Benzamide, 2,4-dimeth INDEX MAME)

RB 925438-79-5 HCAPLUS CF Sensamide, F-[6-(IH-benzimidazo]-INDEX MANE)



THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT HCAPLUS COPYRIGHT 2007 ACS ON STM 2006:1283419 HCAPLUS Full-text LLZ ANSWER/7 OF 2 ACCESSION NÜBER: DOCUMENT NÜBER: TITLE: EFERENCE COUNT.

Transferred uses as Carrespon talegolists and Transferred uses as prespection talegolists and the first preparation parameters of the first preparation of the first properties of the first produced. These fighter, Des Bainde, Ulrich, Derfill, A. German, P. F. The, Wood, J. Stepp. DOCIMENT TYPE:
LANGINGS:
FAMILY ACC. NUM. COUNT:
PATENT DIFORMATION: PATENT ASSIGNER(S):

PM 925435-17-2 HCAPLUS
CM Benzamide, N-[2-(1H-benzimidazol-2-yl)phenyl
morpholinylmethyl)- (CA INDEX MAME)



RN 925415-21-8 HCAPLUS CN Benzamide, N-[2-(1H-benzimidazol-2-yl): INIEX MAME)



EN 925435-22-9 HCAPLUS CN 2-Quinoxalinecarboxamida, NAME)



| 10318.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 10418.232 | 1041

mremium is related to compute of forming 1; preferably a CSs receptor manufact, Organic and Communes A busing in barbonic and statements. Not 1: 123 are districted and of forming a busing in barbonic and statement of the communes of the c 2

indepotal activity; 700 (Therspector)
indepotal subdy; 1055 (therspector)
and prevention of dissess)
and prevention of dissess)
managed subdy; 1055 (therspector)
managed subdy; 1055 (therspector)
managed subdy; 1055 (therspector)
on of trimulation of dissess)
moderation of dissess)

LL2 ANSWER OF 1
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

*** NOTION: ALL CITATION SANIAMES DE TITS ES PROMOTION DE SANIAMES CONTROL SANIAMES DE TITS ES PROMOTION DE SANIAMES DE SANIAMES DE TITS ES PROMOTION DE SANIAMES DE SANIAMES. DIVENTOR (S):

PATENT ASSIGNER(S): SOURCE:

DOCUMENT TYPE:
LANCINGE:
FAMILY ACC. NUM. COUNT: 2
PAIRNT DIPORMATION:

DOCLMENT TYPE: P.
LANGUAGE: E.
PAHLIY ACC. NUM. COUNT: 8
PATENT DAPORMATION:

| MATERIA | MATE

HARPAT 145:314671

interest broadcoptopenia, drug-induced; movel
benzamide derive. as sirtuin-modulating compds. useful in
ment of diseases)

openia, drug-induced, novel M-Fh benzamide derivs. modulating compds, useful in tratment of diseases)

December openance movel is the bentamide derive, as the contember of the contemper of the c

logical activity); EPR (Synthetic preparation); logical activity); PREP ES (thes) T. N-Ph bentamide derive, as sirtuin modulators)), penzamide derivs. as sirtuin modulators)

439126-67-7 700355-06-2 915279-93-5 915279-98-0 915280-03-4 915280-13-6 915280-13-6

- 115280-21-6 115280-21-7 (a.c. 115280-21-7 (b.c. 115280-21-7 (b.c

5 5

EN 401623-34-5 HCAPLES CM Phenol, 4-amino-3-(6-amino-1H-benzimidazol-2-yl)- (CA INDEX NAME)

THERE ARE 6 CITED REPERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAI COPILO COPRIGHE 1907 ACS on STR STREET, STREET LLZ ANSNER, 9 OF 2 ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: PATENT ASSIGNEE (S): SOURCE:

ACCESSION PARTIES.

ACCESS THERE ASE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE PORMA DOCLARENT TYPE: LANGUAGE: FACILY ACC: NUM. COUNT: PATENT INFORMATION:

US 2005-658430P US 2005-705386P

recoyplic compde sirunisadhing of use thereof. The sirunisadhing of use thereof. The sirunisadhing was and literature in cold in successive, municipal management, neuropathy, neuropathy associated thereof the cold in the cold of the c

E

amine, 2,2'-(1,3-phenylene)bis- (9CI)

55

#4##44999## #4##4999## #4## 8.73.85.81.88.75.8 8.73.94.37.0.75.

ğ 8 E

RN 293762-45-5 HCAPLUS CN [2,5-81-1H-bengimidagol]-5-amine, 2'- (4-aminopher NAME)



EM 294891-59-I HCAPLUS CM 2-Plrancarboxamide, N-[3-(1H-benzimidazol-2-yl]phenyl]- (9CI) NANED



100184-10-9 KCAPLUS Benzamide, 4-amino-M-(1-phenyl-1H-benz NAME).



őã

abocycopenic, in adult; preparation of coxamides as modulators of glucocorticoid receptor

stanecarboxamides as modulators of glucocorticoid pical settvity); SPN (Synthetic prepa) *); Blot (Biological study); PREP (Uses)

('Pharmacological serrity); EPP (Synthetic preparation);
benquesta was); EPU (Biological Euchy); PED
rickio); USP (Use)
persisten of theycoccan-emboundes as modifacers of give
per, API, and/or EP-ch metrity) 5 5

acene-11-carboxamide, N-[4-(1H-benzimidazol-2-ylme no-9,10-dibydro-11-methyl- (9CI) (CA DUBK NAME)

for 314033-42-6 HCAPLUS CN 2-Benzothiazolamine, 6-(1H-benzimidazol-2-yl)- (9CI) (CA INDEX NACE)

THESE ARE 3 CITED REFERENCES AVAILABLE POR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAN REPERENCE COUNT:

SOURCESS COPPLICATION ACT ON STR.
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
161.16431
16

DOCUMENT TIPE: LANGUAGE: FAMILY ACC: NUM. COUNT: PATENT DIPORMATION: PATENT ASSIGNEE(S): SOURCE:

ES, 77. 0713 US 200 0720 NO 200 AZ, EM, EB, E DK, DM, DZ, E 20060713 20060720 AT, AU, AZ, CZ, DR, DK, PATENT NO.

US 2006154973
NO 200607632
N: AB, AG, A

| 10518.252 | HOLVILS CONTINUE TOOR AS ON STEE | HOLVILS CONTINUE TOO AS ON STEE | HOLVILS CONTINUE TOO AS ON STEE | HOLVILS AS ON STEE | HOLVILS | HOLVILS | | TOO AND AN ON STEEL AND AS ON

| MATERIA DO | MATERIA DATE | MATERIATION | MATERIA DO |

round scored(s): NARPA 144157158

We see action 18 2009111

We see actions as a provided for experential the immune system and for treat immune related discovers. Therefore of the immune include additionate and the immune related to the see action 18 2009111

We see a second discovers therefore the immune of the second to a majort in seed thereof, much as a summitted distorator systems, and see the immune of distorator systems, architist, splastic among, splitter, best failt show the second in the second sec OTHER SCHEE(S):

All Hew methods are provided immune related disorder immune related disorder immune related disorder immune fitti inhibitor or or or mann p

ceporine, deriva. 71897-07-9, AG 1 12 146535-11-7 18641-56-1, 5US 7762-62-7 254461-73-0, BAK43-9006 1857-39-0, CEP-5214 402857-58-3, GR t

(#15) inhibitors for immus suppression by treating cells for therapy of immus or parcel, disorders)
#15, PAC (Farence)

HE, Date, Passand-depoid a statisty; HBW (Theoreposition and); HE Date, Passand-depoid a study); HBS (Head)
and); HDU, (Madoppical study); HBS (Head)
of the limitation of the consume suppression by treating cells for thereby of the limitation of the consumers o

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
AUTHOR (S):

Actions, the property of the reports against a factor, live to ; Newsting, DitA. A: Remain. History from 0.; Newsting, DitA. A: Remain. History from 0.; Newsting, DitA. A: Remain. L: Lord Knameth. History of Triesdayers. B: Lovia. Jensa L:; Lord Knameth. Nedditional Chemistry and Oncology Research Departments. Meditional Chemistry and Oncology Research Departments. History Chemistry Performance of the property of the property

CORPORATE SOURCE

tole series of small-mol. thrombopoietin receptor agonisti ed. Herein, we discuss the preliminary exploration of y relationships within this chemotype.

reference(s): 28 deriv prepn SAR cytokine thrombpoletin

ropenia foliosi discoli managrapanis; New benzinidazoles as opoletin receptor agonists)

Cherokopropenia, New benizaldazales as theoreopoletin respon against) 2795-91-92 (American) derivity, RCT (Restant); EN 1795-91-92 (Spinist) properation), The (Theoreopeus and (Spinist) (Spinist) properation), The (Theoreopeus areapun); The (Spinist) (The (Spinist) are responsible to the control of the (Spinist) (The (Spinist) are responsible to the control of the (Spinist) (The (Spinist) are supplied to the control of the (Spinist) are supplied to the control of the (Spinist) and (Spinist) are supplied to the control of the (Spinist) and (Spinist) are supplied to the control of the (Spinist) and (Spinist) are supplied to the (Spinist)

RM 71531-4-3 WORMUS GN 4-Thissoldinose 5-[5-(6-(3-4-disethylphemyl)-2-pyridisyl)-18-benzinidasel-5-yllsethylens|-2-thisso-(9CI) (CA INDEX NAME)

ps: 71551;-76-7 KCMFUS Or 4-Thiatolidizone 5-[[2-[5-1],4-disethylphemyl]-2-thiamyl]-1R-benzimidasol. 5-yllenbylanel-2-thixon- (9CI) (CA. DOER MANS)

11. PA: (Presentation);
The (Presentation);
The (Presentation);
The (Presentation);
The (Presentation);
The Presentation);
The (Presentation);
The

ED #77069-93-7 MCAFLUS CN Propagation acid, [[2-16-[4-(1,1-disschylethyl)phenyl]-2-pyridinyl]-1B-

DB 713511-71-8 HOAPUSS
CR 4-Thierolidinone, 5-[[2-[4-(1,4-dimethylphemyl]-2-thiemyl]-1H-b
5-yl]methylene]-2-thioxo- (9CI) (CA DOSK NAME)

20 71531-72-9 HOMELS OH 4-Thiasolidismes 5-[[2-5]-[4-(1,1-disethylethyl)]phenyl]-2-furanyl]-1H-henrishdatol-5-yl]menkylanel-2-thlone- (9CI) (CA DURK MANG)

PR 71351-7-0 MOMENT | 1-1-4 MOMENT |

EDITATION 1.1511-74-1 RCAPLUS

10/538_252 benzinidazol-s-yl]methyl]- (sCI) (cA DDEX SAME)

RB e770e5-95-9 RCMFLIS CR 2-Proprosic expl. 7-[6-(3.4-dimethylphenyl)-2-pyridinyl]-1H-benzinidazol-4-yll-2-methyl- (9CD) (CA 2002 NovG)

EN 877089-86-0 NGAPLUS ON Propusatiois each [2-(6-(3,4-dimethylphenyl)-3-pyridinyl)-lH-perindextol-4-yllmethylmen)- (9C1) (CA DUEN MANG)

Os 4-Thiseolidinose, 5-([2-(4-(1):4checky)-2-bydrocy(1,1'-biplecy)]-3-yl]-18-bentinidanol-5-yl]asthylenel-2-thiono- (9Cl) (0. DOER 1946)

17 THEME ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

MATERIA DE DATE APPLICATION DATE

2 2005/0515 A. 2006/051 DA 2004/12111 2006/121

C 2006/0515 A. 2006/051 DA 2004/12111 2006/121

C 2006/0510 A. 2006/051 DA 2006/051 DA 2006/12111

C 2006/0510 A. 2006/051 DA 2006/051 DA 2006/051

C 2006/0510 A. 2006/051

C 2006/0510 A DOCUMENT TYPE: LANCUAGE: FAMILY ACC: NUM. COLDIT: PATENT INFORMATION:

				-			8	10/538,252	Z			-	- 1		- 1	May L	May 16, 2007
	ij	ĕ	ĕ	ğ	Š.		ij	ă	ä	f,							
	Š	ä	3	ä	3		į	ė	ġ	Ř							
	ğ	72	₹	ģ	Ē		Ľ.	ğ	Ë,	ģ							
	2	ř	ř	ř	E		Š	ġ	ġ	ž,							
ä		ð	ĕ	벋	3		2	ž	ğ	ij							
	7	2	g	ŭ	ē		2	Ř	Ä	BB.							
	H	23	Ľ	Ë	ø	ğ	Ē,	Ħ	Ė	3	¥	ij	Ę	ŗ	g	SE,	
	SI.	ž,	F	£.	3		g	ij	ð	j							
	Š	e	8														
EP 1673348	7			2	~	90	628	щ	ñ	į	2	z		Ň	20040929	:	
ä	¥	Ħ	ð	Ħ	DX, ES, FR, C	ŭ	č	è	Ġ	t	ä	19, 11, 11, 12, 13, 1	ij	ij	¥	Ľ	
	1	12, 51,	ä	Š	Ę	2	ť	Ë	ġ	ij	ď	뎦	Ľ,	PL, SK			
IN 2006 8201104	1070	ğ		4	•	8	5	-	7		120	ž		ñ	20060421	5	
NO 2006001950	6100	9		4	•	20060629	629	*	2	8	950			~	20060502	203	
PRIORITY APPLY, DIPO.	3	5						,	20	ŝ	5072	96		~	20030930	930	
								*	2	5	1831	NO 2004-US31855	_	~	2004092	929	
OTHER SOURCE (S)	9			3	MARPAT 142:355266	5	5526										

5; A61K031-454; C07D043-14; C07D043-02 31.8; X54-619,3; X51-425.406; X51-432.0; X54-437.0; rembocytopenia, treatment of; preparation of as histamine E4 receptor modulators for the treat seases) 136.0 Lic Compounds (More Than One Hatero Atom)) eference(a): 1, 63

ration); RACT (Beactant or Fesgent); USES (Uses) aration of benzimidateles as histonine H4 receptor be treatment of inflammatory diseases)

, 4-[)-[4-(6-chloro-4-methyl-1H-benzim1dazol-2-yl)-3-bexahydro- (9Cl) (CA Didgx MARE)

3-(1620) -- 132 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122 (1720) -- 122

May 16, 2007

vo. 4.1 [Inches]


work of the Limitation plantide and all the characteristics of the property of the characteristics of the property of the characteristics of t

n.3-yl]methanol ological actvicy); SFW (Synthetic preparation) use); BIOL (Biological study); PREP SES (Uses)

COAST (UNEST)

TO PERSONAL OF DESCRIPTION OF THE CONTROL OF THE TRANSPORT OF THE TRANSPORT

EM 648647-21-2 HCAFLUS CH 147-8erindiatable 2-2-(2-chloro-4-11-(4-mathyl-1-pipersatinyllpro 7-7-disethyl- (CA 10705-1448)




BB Hesselv.26-7 NGAFUE The Bearingsols, 2-(2-thoro-4-(3-(4-methyl-1-piperaximyl)propoxylphemyl)-5-(fillocomethoxyl-16f) (CA INDEX NAME)

r3c-0 (cfs) - 0 - 12f



ES state-1-2-0 NCAPLES CH Hi-Searching And Annie (L. 1-chicco-4-(J-(4-methyl-1-piperszinyl)propoxylphenyl) Ch Li-chinethylenyl) (Ch DODEX NACE)




pw 646847-31-4 RCAFUS
GR IM-Benzinidazole, 4,5-dimethyl-2-(3-methyl-4-(3-(4-methyl-1piperszinyllpropoxylphenyl]- (9CI) (CA DDSX NAWS)

103

May 16, 2007

To sesset-4.6 scould control of the control of the



D + (44447-44-3) ECMFLDS Of H-learning and a schlore-2-(3-chlore-4-(3-(1-piperaziny)) propoxy) pheny 6-fluoro-, trifluoroectate (9Cl) (CA DUER NANE)

GK 1

CRN 848847-45-0 CMF C20 H21 C12 F N4 O CN 74-05-1 CN 74-05-1 CN C2 H F3 02


DR 64847-49-4 HCAPLUS
3F IM-Bearingdarole, 6-(1,1-dimethylethyl)-2-(3-methyl-4-(3-(4-methylpiperaringlylpropoxyl)phenyl)- (GA INTEX RANG)

EN 84847-31-6 NCAPLES ON 14-8enzialdende, 5-(1,1-disethylethyl)-2-(3-(4-(4-sethyl-1pipersinyl)butcoxylphenyl)- (5C) (CA INDE NAME)





DO MORRALLID-O REQUESTS
ON 1-Pyrolidization, 1.1-12-chloro-4-(6-41,1-dimethylethyl)-lif-benzimidasol2-Vijfamonylpropyl, -4,6-dimethyl- (CA DEEE NAME)



72 44847-38-1 RCATLS CH Lit-Suttlished 10-1 - Chloro-2-(3-chloro-4-(3-(baxahydro-4-mathyl-1H-1,4-CH Literpin-1-yl)propoxy|pleny|1-6-methyl-1-(5C1) (CL INTEX 5046) _

May 16, 2007

Em 641847-56-7 NGAPU35 GF 14-benzilationie, -7-12-talioro-4-19-(1-methyl-4-piperidinyl)propoxylphenyl) -4-dimethyl- (ST) (CA DGER NAME)



DR #44847-51-8 EGLFLUS

CS 1M:Berninidatole, 2-{2-chloro-4-(2-methyl-1--(4-methyl-1-pipersainyl)propoxylphanyll-4-methyl- (9CI) (CA INDEX NAME)



ps 44840-52-9 HOMPLES.
On 19-Seminationals, 5-chlore-2-(1-chlore-4-(1-14-methyl-1-)
piperminyl)propowylphenyll-4-methyl- (9CB) (CA INDEX BANE)



EN #48147-53-0 HCMFUX CN 18'-Benzindazole, 6-chloro-2-[2-chloro-4-[3-(4-methyl-1piperszinyl]proponylphenyl]-4-methyl- (9cz) (CA INDEX KMS)

RG 64847-18-2 SCAPLUS OF LH-Perzimidatola, 2-(1-flucto-4-(1-(4-methyl-1-piperatinyl)propoxy)pienyl]-4-methyl-(951) (G DDGR NAME)



RD stand-1-4: WCAPLUS CM Lit-dentidation = Comply-2-(4-(3-(4-methyl-1-piperaxinyl)propoxyl-) propoxyl-1 (4-2) (CA IDUX NAWE)



EN 64847-43-4 ECAPLES OF Pipersine. 1-(-(-)-(-(5-(1.1-dimethylethyl)-1H-benzimldazol-2-yl]phenoxy)-1ocobusyl+-eminyl-(9C) (Ch. Duza E046)




May

. 105



EN 44847-54-1 HCAPLUS

CN 1H-Senzimidazole, 5-chloro-2-[1-fluoro-4-[1-(4-methy]-1)piperazimyl)propoxylpbenyl]- (9CI) (CA INDER NAME)



Be session 155-7 HOMPIGS

On Historian databath 15,7-dimetryl. (A DEED 1886)



RN 648847-56-) HCAPLUS

ON 1M-Benzinsidasole, 5-chlorro-6-methyl.2-(1-(4-methyl.1.piperszinyl)butoxylphenyl]- (9CI) (CA INDEX NAME)

No 11847-57-4 MCAPLE On H-Seminatorole, Schlorof-methyl-2-[5-(4-(4-methyl-1-H-Seminatorolphemyl)-, trifinorometae (943) (CA. DURK NAME)




CH 1 CRN 848847-56-3 OMF C23 H29 C1 M4 0

CAN 76-05-1 CAN 76-05-1 CAT C2 H F3 02

6


D) 64847-58-5 HCAFLES CB 1R-Senzinidatole, S-chlore-6-fluore-2-(1)-fluore-4-(1)-(4-methyl-1)-piperazinyl)propoxylphenyl]- (9CI) (CA INDEX 18AC)




pp state-5-5-6 RCAPLES OH Wi-Benzinidatole, 2-(3-fluoro-4-(3-(4-methyl-1-piperatinyl) propoxy) phenyll 5-methyl-(4-71) (ch. 2022 Nobe)



EM 848847-60-9 HCAPLUS



DS 64847-69-8 SCAPLOS OF IN-Renzimidatele, 5,6-dichlore-2-[2-chlore-4-[3-(4-methyl-1-plperazimyl)propoxylphenyl]- (9CI) (CA DUDEX SAME)



EN 648843-70-1: HCAPLUS

CN 1H-Benzimidatole, 6-chloro-2-(2-chloro-4-[3-(4-metbyl-1-piperazinyl)propoxylphenyl]. (CA IMEX MANE)



RN 44847-71-2 HCAPLIS


CH IN-Benzinidazole, 6-chloro-2-[2-chloro-4-[3-(4-methy]-1-piperazinyl)propoxylphenyl]-5-floro- (CA DUEX NAME)



EN 44847-72-3 HCAFLES

CH IM-Sentinidazole, 5-chlore-2-(1-methyl-4-(1-(4-methyl-1-piperaylphenyl)- (9CI) (CA ENERS HAME)

May 16, 2007 1M.Benzimidazole, 5,6-difluoro-2-[3-fluoro-4-[3-(4-methyl-1-pipezazimyl)propoxylphemyl]- (CL DIDEX MANE)





DO MARROLL H.CACLO. ON Hi-dominidatole, 2-(1-chloro-4-(1-theab)dro-4-sethyl-1H-1,4-diarepin-1 pliprepory)phenyll-4,2-diarethyl- (On BURK MAS)




RP REEST-63-2 RCAPUS ON 1H-Benzinidazole, S.6-dimethyl-2-(3-(4-(4-methyl-1-piperazinyl)butoxylphunyl)- (9CI) (CA INDEX MAGE)



EN 148847-64-3 HCAPLUS CN 1M-Benzimidazole, 2-[2-chloro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-

RO 64847-73-4 ROMPLES GH Hi-Benzindatole, 2 (3-chloro-4-(3-(4-mathyl-1-piperatinyl)propoxylphonyl)-6-mathyl- (A DATE NORI) .

EN H4847-74-5 ECAFLES
ON IN-Benzindazole, 5,6-dithlore-2-[3-chlore-4-[3-(4-methyl-3-piperaxinyl)propoxylphenyll- (9CI) (CA.DOEX.NAE) pp 64847-75-4 KCAFLUS CH 14-8emindanole, Schloro-6-methyl-2-[3-methyl-4-[3-(4-methyl-1-14-8emindanole, Schloro-6-methyl-2-(3-methyl-1-)




No. 11847-74-7 (COMPLES OF IN-Sentiablesole, 7:[2-chloro-4-[3-(4-sethy]-1-piperasiny]]propoxy]phony] 4-sethy). (A. DORS NONS)

5,7-dimethyl- (ch. index MAME) nn - 1 (1, 1, 2) - 9 - 1 (1, 1, 2) - 9 - 1 (1, 1, 2) - 1 (PR 1648-1-54-4 NOWAL | PROMISE | PRO



PN M4887-64-5 WCMZUS GN LH-Bernindschole, 2-12-Chloro-4-13-(4-methyl-1-piperatinyl)propoxy/phemyl)-CL L-dimethylenthyl- (cA DUDE NAME)





ER 042847-46-7 HQAPLUS
ON H-Benzindstante, 6-chloro-2-[3-chloro-4-[3-(4-methyl-1-0-plenzatinyl)propoxylphenyl]-5-fluoro- (CA DUES 1840)


ED 848847-77-8 HCAPLUS
CM 1H-Benzimidazole, 6-chloro-2-[3-chloro-4-[3-(6-metbyl-1-piperazinyl)propowylphenyl]- (CA. ENEX MAE)

PD 64843-74-9 HQPALM GH 1P-ParaindArable 2-[1-chloro-4-[1-(4-methyl-1-piperatinyl)propoxylphunyl]-Trillionomethyl- (FCI) (CA DURK NAWN) 2(1) -0 - ((43)) -0 - (1) -0 -

Est #4842-79-0 HCAPUS CH 1H-Burnindateate, S-chlore-4-fluore-2-(1-methyl-4-(3-(4-methyl-1-Appreximyl)propoxylphonyl- (#CL CA IDDE NAME)

EN 648847-80-3 HCAPLUS CH 1H-Benzinidazole, S-methyl-2-[3-methyl-4-[3-(4-methyl-1-pipersinyl)propoxylphenyl]- (9CI) (CA INDEX NAME)

.≃



NO 64847-81-4 NOADING CH Hearthandarde, 2-13-chloro-4-13-(4-methyl-3-piperaninyl) propoxylphenyll-CA DOSE NAME:

DN 44447-44-7 HCMPLMS
CN M-9enzindezole, 6-chlore-5-fluore-2-[1-methoxy-4-[1-(4-methy]-1-piperstinyl]propoxy]phenyl]- (Cn 1923 NAME)

.

May 16, 2007

3

No. 44447-59-9 (Control of the Control of the Contr

EM 848847-94-9 HOLFLIN CM 1H-Senzimidasole, S-chloro-6-methyl-2-[4-[3-(1-methyl-4phperidinyl)propoxylphemyl]- (9Cl) (CM INDEX NAME)

C) -0- (GR2) -0- (GR2)


EN 641847-55-0 ECAPLES ON PRODESTAGESTOR, S-CALOTO-2-(4-(3-(1-eachy)-4-piperidiny)) propoxy) phen (EX) (CA DERS BASE)

); ((a))) - ((a))

RN 648847-96-1 HCAFLUS
CN 1M-Benzinidazole, S-chloro-6-fluoro-2-[4-[3-(1-methyl-4-piperidinyl)propoxylphenyl]- (9CI) (CA ENEX NAE)

D: 44447-15-3 HCALUS GF IN-Seminidatole, 2-(3-chloro-4-(3-(4-methyl-1-piperaxinyl)propoxy/phenyl]-5-methoxy- (SC) (CA INGE NACE)

DB 64847-86-9 (CAPLES OR 11-8eximation2016, 2 (1.5-dibroso-4-(1-(4-setby)-1pripartiny) propoxy [herey] 1-5-(1,1-disetby)etby])- (9CI) (CA INDEX MARE)



ES 64141-17-0 ECAPUM CH 13-Banisatole 1. (2-echony-4-1)-(4-echy)-1-13-Banisatole 1. (2-echony-4)-1-(4-fluoreechy)-(9(1) (CA DIMEN NAMES)



PR 1646-7-9-1 ROMAN CONTROL OF LICENSTRAIN CO

911

May 16, 2007

10 C ((12) -0 - (12) -0 -

DM 84847-97-2 HCMPLIS
DM 1H-Benzimidazole, \$-(1,1-dimethylethyl)-2-(4-(1-(1-methyl-4pipezidinyl)propoxylphenyl]- (9Cl) (CA INTEX NAME)

59 44847-96-3 HOLFLUX CB 14-Bentifedroise, S-methyl-2-(4-[3-(1-enthyl-4-piperidinyl)propoxy)phenyll CC 17-(20 Month Savet)



Ref #4847-59-4 NGPLDS CH 1H-Benzinkale, 7-14-(1-(1-withyl-4-piperidinyl)propoxy)phenyll- (9C1) (Ch DECK NACE)



No. 14144-00-0 RCAFUS OH Discontinedatols (-chloro-2-(2-(lucino-4-()-(1-mathy)-4piperdiny)propowy|portyl-(-cmthy)- (901) (CA DODE NONE)

"- ('au) - o - ('au) - ('au) - o - ('au) - o - ('au) - ('a

E9 #48847-19-2 HGAPLES
GR LH-SenzindsLoke, 2-[1-[1-(4-methyl-1-piperaxinyl)propoxy]phenyl]- (9Cl)
(CA INDEX NAE)

Eq. e4se(7-90-5 RCAPINS GW Wethaume, [-2.10-14.44.emthy]-1-piperatiny]]butcory]phemy]]-1M-benzimidazol 5-yilpenyl-19CI) (CA. DUZK NAME)

DN #48847-31-4 MCAELES CN LN-Benzimidatole, 4-chloro-2-[2-chloro-4-[3-(1-methyl-4piperidinyl)propoxylphemyll-4-methyl- (9CI) (CA INDEX MANG)



10,738,232

No 848848-01-1 HCAPLUS


CH 1H-Benzimidagola, 5-fluoro-2-(3-methyl-4-(3-(1-methyl-4piperidinyl)propoxylphenyl)- (9CB) (CA DDEX NAME)



RN 64864-02-2 HGAPUS GN 1H-Bernimidatole, 4-chloro-2-(2-sethyl-4-(3-(3-61-sethyl-4piperidinyl)propocylphenyll- (9Cl) (CA DRDEN NAME)



Dr 04844-01-1 HCAPUE Ch 1H-Benzindezole, 6-chloro-4-methyl-2-(2-methyl-4-(3-(1-methy piperidinyl)propoxylphenyll- (9CE) (CA DORK NAME)



Rd 141814-04-4 HCAPLUS
CN 1H-Berrightdasol's - S-chloro-2-(2-chloro-4-(3-(1-methyl)-4pararidaryl) propoxyl phrayl | 6-fluoro- (9c1) (CA 1002X MANG)

OR B48848-06-6 HCAPLES

CN IN-Bentimidazole, 4.8-dimethyl-2-(2-methyl-4-(3-(4-methyl-1-piperazinyl)propoxylphemyl)- (9CI) (CA INDEX NAME)

RN 84884-05-7 KCAPLIS GH IN-Sentimidatos, 2-(2-chloro-4-(3-(4-methyl-1-piperszinyl)propoxy)phenyl] 4-methyl-(947) (GL IDDE NAME)

1 - ((42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - 0 - (42) - (42

P. 4484-18-1 EAGLOS (12-chiero 4-1)- (4-seth)-1-piperexxxxy|pbenyll-O-1-sectationscot. 2-(2-chiero-4-1)- (4-seth)-1-piperexxxxy|pbenyll-5-flucro-4-sethy- (4Cl (CA ROMA ROME)



2

DI 84884-30-6 KCAPLUS
GR IN-Bernindarole, 5-fluoro-4-methyl-2-f2-methyl-4-f3-(4-piperidinyl)propoxy)phenyll- (9CI) (GA DOEX NAME)

Reference_11.7 HCPAUS OH 19:30HHEADTACALGE (-C-(1-(1-CAD)'-4-piperidinyl)propoxy)-2-HCHIPSPAUS (-C-CAD) (-C-CA

C1 (123) 3 (123) 3 (123) 3 (123) 4 (12

No 64846-32-F HCAPLUS

CN 4-Piperidinamine, N-(2-(3-chloro-4-(4-methyl-1H-benzimidzol-2-yl)phenoxyl ethyl-H.1-dinachyl- (9CI) (CA INGEN NAME)

3 - 100 - 10

pp 04444-15-1 HCOPULE CF 1H-Serginidatole, 6-chloro4-methyl.2-(2-methyl.4-(2-(1-methyl.4-piperidatyl.osylethorylphenyll.-(9Cl) (CA. DEREN 1990S)

D 44444-11-1 KOLPUS O 1H-bennindatole, 4-chloro-1-[2-chloro-4-1]-(hazahydro-4-mathyl-1H-1,4-datepla-1-yllproposylphenyll-4-mathyl- (9Cl) (CA DUEN SAME)

C1 (CR2)) - C42 (CR2))

ED 84848-13-5 HCM-LLS
CH 18-Bennindarols, 2-(3-(4-(heathydro-4-mcthyl-18-1,4-diarepin-3-yl)butcay)phenyll-4-4-diamthyl-(8CI) (CA DURK BMG)

PR 64848-14-4 KCMPLUS CF IN-Benzinklanden, 5-Ghloro-2-(4-(3-(4-methy)-1-piperazinyl)propoxy)phenyl] (5C) ICA ENEX KAMPREN



ED 04004-15-7 HCAPLES

CR Bennessanther, 7-(6-chlore-4-methyl-1H-bennimidatel.2-yl)-N.MCR Bennessanther, 1-(6-chlore-4-methyl-1H-bennimidatel.2-yl)-N.MCR Bennessyl-6-(1-methyl-4-plperidinyl)propoxyl-(9-21) (CA 19025)

100 - 100 -



stssts.41.9 HOAFLIS IN-Benninidatole, 5:fluoro-4-methyl.2.[3-methyl.4.[3-(1,2,3,4-tetrahydro-1-methyl.4-pyriddhyl)propoxy[phemyl]- [9CT] (CA INDEX NAME)




948848-42-0 HCAPLUS IN-Benzindidatole, S-fluoro-4-methyl-3-19-14-(1-methyl-4-piperidinyl)butoxylphenyll- (9CI) (CA_INDEX_NAME)

Na₂(1-Ci₂)

PR 164184-2-3- RIOPLES O St. 4-Diazepin-some 4-D-(4-Us-(1-Us-bunthy)sthy))-18-bunthaddrol-2-yl)-3-methylphenoxylpropyl)beauhydro-1-methyl (9CD) (On DIEE NAME)

DD 64846-27-1 HCAPLUS

CM 1H-Benzimidazole, 6-chloro-4-methyl-2-[2-methyl-4-[3-(4-phperidinyl)propoxylphenyl]- (9CI) (CA DNEX NAME)



70 18-5000 (A. DORG NAME) -2-(3-(4-(3-methy)-4-piperidiny)) butcoy) phenyl)-(5C) (A. DORG NAME)




RN 848148-46-4 HCAFLUS
CN 1H-Benrinidazole, 4,5-dimethyl-2-(3-[4-(1-methyl-4-piperidinyl)buroxylphenyl)- (9C1) (CA 1MER MACE)



EN 84848-47-5 HCAPLUS
CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[1-[4-(1-methyl-4-pperidinyl)butoxy]phenyl)- (9c1) (CA EUEX RAME)



29 #48844-48-6 RCAFLES CW IN-Seminaldatole, 4,6-dimethyl-2-(2-methyl-3-(4-(1-methyl-4-piperidinyl)butcoxylphenyl]- (9CI) (CA INUEL MANE)



124

P) 64846-45-7 HCAPLES
G: IN-Benzimidazole, 6-chloro-4-methyl-2- (3-methyl-3- (4-13-methyl-4-piperidisyl) butosylphenyll- (9CI) (CA DURK MANE)

EN 646848-51-1 HCAPLES

CN 1H-Benzimidazole, 5-fluoro-4-methyl-2-(3-[3-[4]-methyl-4-piperidinyl)cxylpropoxylphomyl)- (9CE) (CA INGE NACE)



DI H-BERLINGAROLE, 4-Chirro-4-methyl-2-16-13-1(4-methyl-1-piperatinyl) proposyl-3-pyridinyll- (SCI) (CA DUEA NASE)



127

No. (1983) 3

Bi ##### 20-4 HOAPUS
Cl IN-Benzimichzole, 4,6-dimethyl-2-[4-methyl-4-[1-(1-methyl-4-piperidinyll)propoxyl-1-pyridinyll)
(9CI) (CA INDEX NANC)



DF 14884-71-5 RCAFLES

CH 1H-Benzinidatole, 4-thoro-2-(4-methyl-4-(1-(1-methyl-4-piperidinyl)proponyl-1-pyridinyl)- (9cl) (Gn Dunx NAME)



PD 44441-73-6 HONDA 2-14-caltoro-4-15-(1-sath)-1-piperidiny])propoxy)-1-pyridiny])-1-filuzro-4-sathy]- Prid (CA DEEN NAG)



EN 84848-74-8 HCMFLMS

CM 1H-Benzinidazole, 2-(4-chloro-6-(3-(1-metby)-4-piper
pyridinyl)-4-metbyl- (9CI) (CA INDEX NAME)

28 N8848-57-7 HCMPLUS CH 'H-Serritudatola, -renthyl-2-(6-(3-(4-mathyl-1-piperazinyl))propoxyl-3-(21 Michyll-14-71 (CA IDDEX NAME)

N (CH3)) - (CH3)) - (CH3))

DN 84844-56-6 HOATJS
CN 18-Benimidatole, \$-fluoro-4-methyl-2-[6-[3-(4-methyl-1-piperathyl) piperathyl) propoxyl-3-pyridinyll (9c1) (CA 1878X NAME)



DO 46868-59-9 KCAPLA CH 1H-Seminiationie, +centryl-2-[6-[1-(1-emethy]-4-piperidiny])propoxy)-3-Trickinyl, (Wrill (G. 100K MAME)





EN 648848-63-5 HCAPLUS

DB M444-75-9 HOLPLUS

OB 1H-Seminidatels, 4-chlore-2-(4-chlore-4-12-(1-methyl-4-pperidaryl)+-pyridaryll-4-methyl- (9CH) (GR INCE BANG)



PR states n.e. s. (2014) OH 11-Brazi indensie, 2-(s-chlore-s-()-(1-esthyl-s-piper(dinyl)propony)-1-pyridinyl]-s,s-dimethyl- (9CI) (CA INCEX MANGI



DB 64844-77-1 KCMLMS CB IN-Benishanchs 2-(4-mshboy-4-(3-(1-mshby)-4-piperidinyl)propoxy)-3-pyridinyl)-4-mshby-1951) (CA EGEX EANE)



pp 64644-79-3 ECNEUM CH 1H-Bearladacle, \$-(lucro-2-(4-methoxy-6-(3-(1-methy)-4-1H-Bearladay)|propoxy)-3-pyridiny|]-4-methy!-(9C1) (CA DATEX HAME)

DN MARKE-64-6 SCAFLES CR 18-Seminicharole, 6-chloro-4-sethyl-2; (4-sethyl-4-(1-4)-sethyl-4-pherichnyllpropoxyl-3-pyrichnyll- (907) (CA 1862K 1998)



pp 64846-67-9 HOAPLE ON IN-Bernindarole, 4-setbyl-2-[4-setbyl-6-[3-(1-setbyl-4-piperidinyl)propoxyl-3-pyridinyl]- (9c1) (G. INEX RANE)



20 #4848-66-0 HOAPINS ON IN-Benninderols, S-fluoro-4-methyl-2-(4-methyl-4-(3-(1-desthyl-4-piperidinyl)-1-97(dinyl)- (9CI) (CA.INGE.RANG)



pp #44848-69-1 HCAPLES


CB IN-Bernicharole, 4,5-dimethyl-2-(4-methyl-4-(3-(1-methyl-4piperidinyl)propoxyl-3-pyridinyl)- (9CI) (CA INDEX NAME)

53

May 16, 2007

m^o (Gt₂) 3 — m

DE MARKATO-6 NONTES OF 11-Sentimidatols 5-fluoro-t-methyl-2-(6-13-(1.2.2)-6-tetrahydro-1-methyl-4-pyridinyl)propowyl-2-pyridinyl]- (9CI) (CA 10CEA MAG)



PR MARKALELS RODALELS RODALELS REPUBLICATION OF BEHAVIOR THE REPUBLICATION OF BEHAVIOR TO PARTICINAL PROPERTY 1-1-PYRIGINAL (OR DURK NAME)



DR MARNATA-0 NOATIES CR 18-Seminatable 6-chlorov-0-mthyl-2-(6-13-(1,2,3,5-tetrahydro-1-methyl-4-pridingl)proponyl-2-pyridinyll- (8CI) (CR DEEK NACE)



DO 041446-85-1 NCAPLA OF 14-Bennindanolo, 4.5-dimethyl-2-1[-(]-(1,2,),6-tetrahydro-1-mathyl-4-Traduylipropowyl-3-pyrathyll-(9CII (CA.IRUEN NAME)

욢



DI 648141-46-2 HOAPUDS
CH IN-Bentraldatole 4,6-dimethyl-2-(6-()-(1,2.),6-tetralytro-1-methyl-4-pyridinyl)proposyl-2-pyridinyl- (9-CI) (CA INDEX NAG)

DO 0.000-17.) ROMAN CONTROL OF THE C



133

May 16, 2007



sets4-05-2 RCAPLES H-Senzidabole, 5-(5-chloro-2-(4-(1-methy)-4-piperidiny))butcoy)-4-pyridiny)1-4,5-dimethyl- (921) (CA. DREE RAME)



PR 04849-06-9 RODELLO OH PLF4mariabole, 4,4-dimethyl.2-(1-(4-(4-methyl.1-piperazinyl)butoxyl-4-Trifathyll-(4C1) (CA INDER 0408)





pp 64846-55-1 RCAPAIN GF H: Seminatoriol- 2-(5-brow-2-(4-(1-setby)-4-piperidiny)) butoxy)-4-pr: Archard 1-5-fluoro-4-methy- (9CI) (GA INDEX NAME)





BARBAR-97-5 HCAPLUS CH 1H-Benzimidazole, 2-[5-bromo-2-[4-(1-sethy]-4-piperidiny]]butoxy]-4-pyridiny]]-4.4-dimehyl- (9KI) (CA DUEK NAME)



Est 84844-39-4 HCVLVA CH 14-9mm1imidacola, 2-(5-bromes-2-(4-(1-mathy).4-piparidiny)lbutcoxy)-4TYTCLDY31-4;5-dimethyl- (5-) DUEX NAME;





ED 84849-11-6 HCMFUS

CM IH-Benzimidazole, 6-chloro-4-methyl-2-[2-[4-(4-methyl-1-piperaximyl)hutoxyl-4-pyridimyl)- (9CI) (CA EDDEX MANG)



pp 44445-17 ROMAN (American Cherabydro-4-methyl: H-1,4-diszepla-1 (Allenewyl-4-pyridinyl)-4-methyl- (GCI) (CA DOMANAN (AME)



EN 848848-16-1 HCAPLUS CM IH-Benzinidazole, 2-(2-(4-(bexahydro-4-methyl-1H-1,4-diazepin-1-yl)butoxy)-

44844-99-7 RCAFLSS
ON Literaturals and Carlo Carlo Carlo (4-(1-methyl-4-piperidinyl) butcay)-4H-Bentlandanole - (1-(1-bibaro-4-methyl-4-piperidinyl) butcay)-4(2A DROK RANG)



Est state; no. 1 HCALLAND (1994) 14. (1-sethyl.4-piperidinyl)butcxyl.4-piperidinyl)butcxyl.4-fibrednyl.1-5-fil.1-dimethylethyl) - (9Cl. IODER 1990E)



EN 848149-01-4 MCAPLES

CN IN-Benzintdarole, 5-(1,1-dimethylethyl)-2-(2-(4-(1-methyl-4-piperidinyl)buroxyl-4-pyridinyl)- (9C) (CA EDEE NAE)



En sesses-co-s HCDFLES ON HF-Berrindatole, 2-[5-chloro-2-[4-(1-methyl-4-piperidinyl)]butcoxy)-4-pyridinyl]-5-fluoro-4-methyl-(9C1) (CA INDEX MORE)

4-pyridinyl]-4,5-dimethyl- (9CI) (CA INDEX NAME) DN 4684-17-2 HOUPILS ON IN-Bentinderole, 4,6-dimethyl.2-[2-[4-(1-methyl-4-piparidinyl)butony]-4-pyridnyl- (971) (0, nom Now)



EN 64844-10-7 MCPUP. CH 1M-Sanifachole 4-methyl-2-[2-[4-(1-methyl-4-piperidinyl)butoxy]-4-7-7-fathyl- (9-7) (Ch 1572 MOR)



DB 648849-21-0 HCAPLUS
CM 1H-Bernzimichzole, 5-fluoro-4-methyl-2-[2-[4-(1-methyl-4-pperidinyl) butcaxyl-4-pyridinyl]- (9CT) (CA DDDEX NNWE)



Eg: 04844-23-0 HCQFLS GR: 18-Senzindande: 4.5-dimethyl.-3-(2-(4-(1-methyl-4-piperidinyl)butcay)-4pyradnyll (9CI) (CA. DOME. NOME)

1 (202) -C- 1 (202

EN 648849-24-1 HCAFLES

CR 1R-Benzimidatole, 6-chloro-4-methyl-2-[2-(4-(1-methyl-4piperidinyl)bucoxyl-4-pyridinyl)- (9CI) (CL EDEK NAME)

C1 (SED) -0 - (SED) -0

FOR MEMBER 25-2 HCAPLUS

CM IN-Segrindazole, 5-chloro-4-methyl-2-[2-[4-[1-methyl-4-piperidinyl]bucoxyl-4-pyridinyl]- (9CI) (CA DUDEX NAME)



EN #4848-26-3 HCMPLES ON Di-Seminatoria, 5-(1,1-dimethylethyl)-2-(2-(4-(4-piperidinyl)butoxy)-4-Trickhyll- (9CT) (CA EDEEX NOWE)

139

May 16

pp 14143-14-5 EGAPLE CH 1H-Bertinidatole, 2-(1-chloro-2-(4-(1-methyl-4-piper(dinyl)butoxy)-4pyridinyll-5-fluoro-4-methyl- (9C1) (Ch INEK 1866)

A CORES & CORE

20 M4849-37-6 ECAFUS
CN 1M-Bernindarole, 2-19-chloro-2-14-(1-methyl-4-piperidinyl)butoxyl-4-pyridinyll-4-4-dimethyl- (9C1) (CA DUEX MASS)

EN BATTAS-39-8 SCAPLUS

1. Pu - 1 (CH2) 1 - CH2) 1 - C

DO 0.0004-28-5 RCDFLDS CF II-Demzindatobe, 2-(2-(4-(1-ethyl-4-piparidinyl)butcoy)-4-pyridinyl]-4,5. dimethyl-(9:1) (ch. ddm. 1000)

DB 64849-29-6 HOAFLAS
CB 1H-Benzimichzole, 4.6-dimethyl-2-[]-methyl-2-[4-(1-methyl-4-piperidinyl]]butoxyl-4-pyridinyl]- [9CI] (CA 120EX NAME)

11((22))

RN 848849-31-0 HCMFLUS CN 1M-Bezzimidazole, 4-methyl-2-[3-methyl-2-[4-(1-methyl-4piperidinyl)butoxyl-4-pyxidinyl]- (9CI) (CA INDEX NAME) 140

| 10538.225 | May 16, 200 | May 18, 200 | Ma

EN #4#849-40-1 HCAPLES CN 1H-Bernimidatole, 5-fluoro-4-methyl-2-[5-methyl-2-(4-(1-methyl-4piperidinyl)butoxyl-4-pyridinyll- (943) (CA DGER MANE)

1 (CED) 1 (CED

PR 14448-4.1.2 (COPUL) Of 11-Remaiks/danole, thorn-t-fluoro-2-(5-methyl-2-(4-(1-methyl-4piperidinyl) buconyl 4-pyridinyll- (9Cl) (CA INDER NAME)

Pr 44849-42-3 HONLUS Or 19-Searchaideole 5-(1)-dissebyletbyl)-2-(5-sebyl-2-(6-(1-sebyl-4piperiddnyl)batosyl-4-pyriddyll- (9CJ) (CA DEEK BAND)

EN 848849-43-4 HCAPLES

1 (12) -0 - (2)

DV 64846-12-1 NCAPUS
CM 1N-Nemzimidziole, 4-chloro-4-methyl-2-(1-methyl-4-pjeridinyl) becoay|-4-pyridinyl]- (9Cl) (CA IDEE NAME)

) (203) - (203

Est 14144-13-2 (CALL)

OH 19-3mrzieldezole, 2-(3-chloro-2-(4-(1-sathyl-4-piperidinyl)batoxyl-4FYTALDY)l-4-sethyl- (9CT) (CA DOZE MMS)

RN 44849-35-4 HCAPLES

CN 1H-Benzimidazole, 4-chloro-2-[3-chloro-2-[4-(1-methy]-4-ppridinyl)butoxy]-4-pyridinyl]- (SA EDESK HANG)

| 10/58/22| H: Bernimidazole, 4,5-dimethyl-2-(5-methyl-2-(4-(1-methyl-4piperidimyl)butoxyl-4-pyridimyll- (9CI) (GA DEREK MASE)

ED 1419-14-1 NOVEM CO 11 section 200 x 15-chloro-2-14-(1-mathy)-4-piperidinyl)butony)-4 pyridinyl 1-4-domethyl - 1901 (CO 2002 1909)

No. C1 (583) 4

RN 84849-45-6 HCAFLAS
CN 11-Semindatole, 5-chloro-2-(5-chloro-2-(4-(1-methyl-4piperidinyl)bucoxyl-4-pyridinyll- (9c1) (CA INDEX NAME)

-1 (212) -0 -1 (21

Es 848849-47-8 RCAPLES CR H-Sennimicanole, 2-(5-chlore-2-(4-(1-methy)-4-piperidinyl)butoxy)-4-

essag-49-0 RCMFLD: 1H: Semm_inichanlo: 2-(5-brown-2-(4-(1-methyl-4-piperidinyl)butoxy)-4-pyrichanlyl-3-chloro-6-fluoro-(941) (CA. INGE. NAME)

ED 44844-50-3 HCAPLUS CF 11-Seminatable - 1(5-bromo-2-[4-(1-methy]-4-piperidinyl)butnayl-4-Trickinyll-8-caloro- (9CT) (CA. IDGE HANG)

145

1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999 | 1999

OTHER SCOTTCE (8):

AB The invention disclose combination that an 110-hydroxysteroid dehydroxysteroid selection servector separate for treating sees for baying inflammation as a compount, an associated with glucoricoid seespoor as

48



HONES COPRIME 2007 ACS OF STEP SCHEMENT PROFILE CALL-MAN. CONTRIBUTION OF ACCOUNTS OF STEP Use of Appricaments and prevention of various events and recognist for treatment and prevention of various events and management for treatment and prevention of various events and interpret to be prevented to of various events and prevention of various preventions of the prevention of the pr PATENT ASSIGNEE(S): SOURCE: DIVENTOR (S):

DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

APPLICATION NO. PATENT NO.

US 200501010 A1 20050217 US 2004-123546
IR 200501010 A A 20050217 US 2004-15173
IR 200111500 A A 2005010 IN 2001-15160
IR 20011500 A A 2005010 IN 2001-15160
IR 200111500 A A 2005010 IN 2001-15160
IR 200111500 A A 2005010 IN 2001-15160
IR 200111500 A A 2005010 A A 2005010 IN 2001-15160
IR 200111500 A A 2005010 A A 2005010 IN 2001-15160
IR 200111500 A A 2005010 A A 2005010 IN 2001-15160
IR 200111500 A A 2005010 A A 2005010 A A 2005010 A A 200501

8 8 1

mist hydroxysteroid dehydrogename proprieted agonist combination to associated diseases and minimize s

IC ICH ASIK ICA ASIK ICA SIA16500D CC 1-8 (Pharr Section C: IT Purpura (

erence (s): 63

11 reputs a tumostic fatherwise properties use of dippridenals.

(Extractic fatherwise companions in taxaparia for treatment and receptual poly and the companions in taxaparia for treatment and processing the companions of the c

14.0 min. over 1. (1.1. min. over 1.1. min. over 1. 25

10 HOUSE COPPLIENT 2007 ACS on STD.
2004: PRINCE HOUSE SALESAND.
ALTHOROTY.
CARLINGTON DESCRIPTION AND SALESAND.
CARLINGTON DESCRIPTION AND SALESAND.
CARLINGTON DESCRIPTION AND SALESAND.
CARLINGTON DESCRIPTION AND SALESAND.
Inclination associated disease and to ministe the inclination associated disease and to ministe the separate therety.
Inclination associated with pieceorizoid receptor agont therety.
For any sales associated with pieceorizoid receptor agont therety.
For any sales associated with pieceorizoid receptor agont the sales associated with a pieceorizoid receptor agont the sales associated with a pieceorizoid receptor agont the sales and th

DAYENTOR(S): PATENT ASSIGNEE(S): SOURCE:

DOCUMENT TIPE:
LANGUAGE:
FAMILY ACC: NUM: COUNT:
PATENT INPORMATICN:

100 APPLICATION NO. DATE 8 : PATENT NO.

147

station of the state of the sta ē ā

Ed 17859-63-4 NGAPLUS CH Bernote ecid, -15-(11,3.0-rrimethyl-4-azabicyclo(3.2.1)ect-4-yl)carbomyl)-li-benindanol-2-yl, -methyl ester (95) (CA DOMX NAME)

D 71889-65-1 MCAPLE G 6-Anhicyclo(1.2.1)cotane 1.3.3-trimethyl-6-[(2-(2-nitropheny)]-18-beninderol-5-yllcarbonyll- (9C) (CA DDER BANG)

LIZ ANSWER 17 OF 13 HOAVING COPPLIENT 1001 AGE ON STD.
ACCESSION PROBES.
THE STREET HEADY.
THE STREET HEADY.
PROPERTY HEADY.
P

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COL PATENT INFORMATION:

151

Sisteria, 1. Dimethylphomylboromic acid with the control of the co

out (The propertion); TRV (Therpwortio use); Biol.
My; PEPPE (Preparation); USES (Dees)
and (organistion of non-peptide thrombopoietin mismics
thrombooyloogus)

idinone, 5-[[2-[6-(3,4-dichlorophemy])-2-pyridinyl]-lH-rol-5-yl]methylene]-2-thioxo- (9CI) (CA IMDEX MAME)

ns 713511-68-3 KOLEGOS Os 4-Thiseolidinon, 5-[[2-[6-(3.4-dimethylphenyl]-2-pyridinyl]-1H-berrinidarol-5-yllmethylmel-2-thiono-(9C) (OA INDEX NAME)

armaceuticals)
robs-reference(s): 1, 25
robs-r

TI Internal 28 K

(edjuvants; preparation and formulation of mon-peptide thromopoletin almatic for treatment of thrombogropeaea)

II. Optionar receptors

II. Boll Modelptida (man undimentingle) IDL (piological randy)

II. Spons to anterposite to confinite ration of preparation and formula of temporal and thromboguetin manarics for treatment of temporal decreaming in the commence of the preparation and formula the commence of the preparation and formula the commence of the co

emptor

1 (Raiogical study, unclassified; Biol (Biological study)

mater, preparation and formulation of non-peptide thrombopolation

with for treatment of thrombopylopeats)

Livery systems.

males; preparation and (ormalation of non-peptide thrombopoletin
title for treatment of thrombopytopenia)
tes and Immunoglobulins

Peptide. biological studies

Li. 70 (Threpsolute use) 100 (Biological study); USES (Dess)

Li. 70 (Threpsolute use) 100 (Biological study); USES (Dess)

Li. 70 (Threpsolute use) 100 (Biological study); USES (Dess)

Li princhpolute use and permitted on threshooprogenia.

Threshop (Alond)

Li farea. Librahooprogenia, treatent of threphrate on testiment of use and threshop (Biological studies) on peptide thredboopsels missite on treatent of threshop (Alond)

Threshop (Alond)

nhancement of production of, preparation and formilation of non-peptide production nimetics for treatment of chrombocytopenia) autrov

cement of survival and/or proliferation of; preparation and atton of non-peptide thrombopoietin missizes for treatment

sebecytopenie; preparation and formulation of subopoletin mimerics for treatment of

(indupherais; proparation and formulation of non-poptide thromboposetin minetic for transment of thrombopyopesia) Rematopolesis ujections; preparation and formulation of non-peptide thromatics for treatment of chrombeographenia pheresia

20 715511-49-4 HCAPLUS CB 2-Propensite acid, 1-[2-(4-(4-(1,1-dimethylethyl)pinny]]-2-pyridinyl]-1H-Pernindanol-5-yll-2-methyl-, (2B)- (9CI) (CA DURK NAME)

pp 713511-70-7 HCAPLUS
CM + "Takeolidismos" 5-[[2-[3-(3,4-dimethylphemyl)-3-thiemyl]-1H-benzimidazolS-yl] = Ebyl (Eps) 2-thion- (9CI) (CA INDEX NAWE)

RN 713511-71-4 MCAPLUS CN 4-7.fiseolidama, 5-([2-(4-(3,4-dimethylphenyl]-2-thienyl]-1H-benzimidarol 5-yllmethylenel 2-thioro- (9ct) (Ch. DUCK NAME)

PR 71351-73-9 MCGM-72-16 (4-(1,1-disschylsthyl)phunyl)-2-furmyl)-18-OR +Thatelidinome, 3-[(2-(5-(4-(1,1-disschylsthyl)phunyl)-2-furmyl)-18-benniandmol-5-yl]methylwnd-2-thicore (9CI) (CA DUMI MANE)

imegakaryocytopoiesis, promotion of; preparation and formulation of our-peptide thrombopoletin mimetics for treatment of

on and formulation of non-peptide thrombopoletin mimetics thrombocytoyeans) The Designative systems (Authorities of the Section of the systems (Authorities for treatment of the subscripesia)

The interior of the statement of the subscripesia)

treatment of the consequence of non-paperine thrombopules in minuties for the consequence of the consequence

of steen cells of peripheral blood, enhancement of; preparation and non-peptide thrombopoletin mimetice for treatment of combonyropenia) formalati

Memoryary community of production of propagation and formulation of non-peptide throughpoint instantion for treatment of chromadosyropanas)

Through delivery system

(tablets; preparation and formulation of non-peptide thrombopoletin

for treatment of thrombocytopenie)

plant and Transplantation
brombooytopenia due to; preparation and formulation of
applies thrombopolatin mimerics for treatment of Ħ

brombocytopenia, treatment of; preparation and formulation of an emptide thrombocytin mimetics for treatment of respection for treatment of members of the contraction of the contractio

ombocytopoiesis, promotion of; preparation and formulation of peptide thrombopoietin mimetics for treatment of

The characteristic content of the ch

153

71351-73-9 (CAPLES)

- This and it defenses 5-([2-(4-(1,1-diserby]athyl) [1,1-bipheny]]-3-y]]-111-berring desoi-5-y] berring desoi-5-y] berring desoi-5-y] berring desoi-6-y]

represention of cotahydro-18-regulation; 1-flinable-4carbonalide derivative as selective glucocorrisoid
and inflammatory conflictus research of accomman
and inflammatory conflictus research of accomman
All, head of, aster, Gasen D.; Ballowe, James M.;
Forche, Stockair, Peter J.; Teta, James R.; Taylor,
Gorden, Coolies, Joung L.
Herck G. Co., Inc., USA
Forche, T. Taylor,
Forche, T. Taylor, 113 ANDREA 74 OF 23 HOADLES COPTIZET 2007 ACS ON STRY
ACCESSION NINGER: 100.2013001 HOADLE PAINTERN
100.201301 100.201300 PRESENTATION OF CONTROL OF CONTR

PATENT ASSIGNEE (S):

DOCUMENT TYPE: LANGUAGE: PANTLY ACC. NUM. COUNT:

PATENT INPORMATION

MARPAT 140:287380

(US 2002-191110P P 20020528 WO 2001-US16888 W 20010528 B2 20061121 US 7138530 PRIORITY APPLA: INPO.:

MARPAT 140:16639

OTHER SOURCE (S):

8 2 t

631903-02-1P	631903-08-72	631903-16-72	631903-26-9P	631903-39-4P	631903-49-6P	631903-57-6P	631903 - 63 - 4P	631903-68-9P	631903-73-62	631903-78-1P	631903-13-1P	631903-08-39	631903-93-0P	631903-99-6P	631904-04-6P	631904-09-1P	631904-14-8P	431904-19-1P	631904-26-2P	631904 - 32 - GP
631903-00-8P	631903-07-6P	631903-14-5P	631903-24-7P	631903-37-2P	631903-47-47	\$31903-56-5P	631903-62-39	631903-67-0P	631903-72-5P	631903-77-0P	631903-82-7P	631903-87-2P	631903-92-9P	631903-98-52	631904-03-5P	631904-08-0P	631904-13-7P	631904-18-2P	631904-24-0P	631904-31-95
631902-98-29	631903-06-5P	631903-12-37	631903-22-SP	631903-33-8P	631963-45-2P	631903-55-4P	631903-61-2P	631903-66-7P	431903-71-4P	631903-76-9P	631903-81-6P	431903-66-1P	631903-91-8P	631903-97-4P	631904-02-4P	631904-07-9P	631904-12-6P	631904-17-1P	631904-22-8P	631904-30-EP
631902-96-02	631903-05-4P	631903-10-1P	631903-20-32	631903-31-6P	631903-43-08	631903-53-2P	631903-60-1P	631903-65-6P	631903-70-3P	631903-75-8P	631903-80-5P	631903-85-0P	631903-90-TP	631903-95-2P	631904-01-3P	631904-06-8P	631904-11-5P	631904-16-0P	631904-21-7P	631904 - 29 - SP
631902-94-8P	611903-04-32	631903-09-8P	631903-18-92	631903-28-1P	631903-41-8P	631903-51-0P	631903-S8-7P	631903-64-SP	631903-69-0P	631903-74-72	631903-79-2P	631903-84-92	631903-89-4P	631903 - 94 - 1P	631904 - 00-2P	631904-05-72	631904-10-4P	631904-15-9P	631904-20-6P	431904-28-4P

Treatment with athyl-4,4.4- trifluorocrocomate followed by dropwise addition of EC1) gave the target I (R1 + G7), R2, R3 + R1, X + C0, R4 + GR1).

The Asia ocyclic Compounds (More Than One Hetero Atom) t

| Company | Comp

86

29

- 1			10/538,252		May 16, 2007
	631904-34-2P	631904-35-3P	631904-37-5P	631904-38-6P	631904-39-7P
	631904-40-0P	631904-41-1P	631904-43-3P	6313904-45-5P	631904-46-6P
	631904-48-8P	611904-49-9P	631904-51-3P	631904-53-5P	631904-55-7P
	631904-57-9P	631904-59-1P	631904-61-5P	631904-63-7P	631904-65-9P
	631904-67-1P	631904-69-3P	631904-71-7P	631904-73-9P	631904-75-1P
	631904-77-3P	631504-79-5P 631904-81-5P	1904-81-59		
	631904-83-12	631504-85-39	631 904 - 87 - 5P	631904-89-7P	
	631904-91-1P	631904 - 93 - JP	631904-94-42	631904-96-6P	631904 - 98 - 6P
	631905-00-5P	631905-02-7P	63190S-04-9P	631905-06-1P	631905-cs-3P
	631905-10-7P	631905-12-9P	631905-14-1P	631905-16-3P	431905-18-5P
	631905-20-9P	631905-22-1P	611905-24-1P	631905-26-5P	631905-28-7P
	631905-30-1P	631905-32-3P	. 631905-34-5P	631905-36-7P	611905-38-9P
	631905-40-3P	631905-41-4P	631905-42-5P	631905-44-7P	631905-45-EP
	631905-47-0P	631905-49-2P	631905-51-6P	631905-53-8P	631905-54-9P
	631905-55-0P	631905-57-2P	631905-59-4P	41-19-5061t9	631905-63-0P
	631905-65-2P	631905-67-4P	631905-69-6P	631905-71-0P	411905-75-4P
	631905-77-6P	631905-79-8P	631905-81-2P	631905-82-3P	611905-84-52
	631905-86-7P	611905-88-9P	631905-90-3P	631905-92-5P	631905-94-7P
	631905-96-9P	631905-98-1P	631906-00-8P	631906-02-0P	631906-04-2P
	631906 - 06 - 4P	631906-08-6P	631906-10-0P	631906-12-2P	631906-14-4P
	631906-16-6P	611906-18-8P	611906-20-2P	631906-22-4P	631906-23-5P
	631906-25-7P	631906-27-9P	631906 - 29 - 1P	631906-31-5P	631906-33-7P
	631906-35-9P	611906-37-1P	631906-39-39	631906-41-7P	631906-43-9P
	631906-45-1P	631906-47-3P	631906-49-5P	631906-51-92	631906-53-1P
	631906-55-3P	611906-57-5P	631906-59-7P	d1-19-9061c9	411906-65-5P
	631906-67-TP	•			
			· · · · · · · · · · · · · · · · · · ·	and the state of t	

phenecarboximidamide, 4-[[]-(]-methyl-1H-benzimidarol-2-nyl]sulfonyl]-5-(methylthio)-, trifluoroacetate (9Cl) (CA INDER thiophene amidines for treating compleme ā ö

3

HCAPLUS COPTRICHT 2007 ACS on STR 2003:951014 HCAPLUS FULL-LOXI 140:16639

PATENT ASSIGNER(S): SOURCE: DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COP
PATENT DIPORMATION: PATENT NO.

ccabytronaphthoindole-4-carbonamide derive, as selective expetor modulators for the treatment of autoimmume and ittions)

moological activity); SPM (Synthetic preparation); to mas); BIOL (Biological study); PEP USES (Unes)

OH 2 CON 16-05-1 OHP C2 H F3 02

Ed (11964-81-9 HCAPLES OF 2-Thiophere-troinsidente, 4-(13-(1H-benzimidasol-2-yl)phenyl]sul(cmyl]-5 (cathyllaio:, triflumroacetate (9C) (CA INGE NAME) -5

CEM 631904-80-8 CHP C19 H16 M4 OZ S3

ON 2 CON 76-05-1 ON CO H 73 02

6110-41.1 HCAVLE 2. Thicphemearboximideale, 4-[[1-(1-ethyl-lif-benzimidazol-2-yliphorplisuifonyll-5-(sethylthio)., trifluorescence (9CI) 60009.

CH 1 CDM 631954-82-0 CHP C21 H20 M4 C2 S3

May 16, 2007

2 76-05-1 C2 H 73 02 5 B

\$1190-95-1 HCMFLDS IN-Bernzindezole-1-propansenifonic acid, 2-[1-[19-(aminoiathomethy]]-2 [methylchio]-1-thienyllaulfomyllphenyll-, trifluoroacetate (9CI) (CA INDEX NAME)

CEN 631964-84-2 ONF C22 H22 N4 OS S4 5

2 76-05-1 C2 H F3 02


8 8 8

163

As selective nlators) (762-59-3P 614752-60-6P

etic propazzion): Tor (Therapentio use); BIOL udv): PET (Propazzion): USES (Uses) of IN-bernof():Indarol-5-yl derive, as selectiv allatora):

response to Blebmo(flindanol-5-yl deniw. as selective gl. response bollsten)
44475-2-3 ROAMBA
4445-2-3 ROAMBA
4.445-5-3 ROAMBA
4.445-5-1,7-1-6-flindanole, 5-118-bennindanol-5-yl)-1-(4-flindanole, 5-118-bennindanol-5-yl)
4.445-5-1,7-benninge-4-setbyl-, (448.5)-(957)



61762-59-1 NGAFLUS Cyclogent[[indexcle. 9-(IN-benzimidatol-1-24]]-1-(4-fluoropheny]]-1,c,e4,5,f-7-benabydro-4s-methyl-, (48,55)- (9CI) (Ch. INDEX MANG)

8

1) HCMPIES CONTRICTED ANALASSES THE ENTRY OF PROPERTY OF THE P THERE ANS 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT LLZ ANSWER /20.0P ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: PATENT ASSIGNME(S): SOURCE: DIVENTOR (S):

DOCHENT TIPE: LANCUACE: FACILY ACC. NUM. COUNT: PATENT DIFORMATION:

| March | Marc MATTER 70.

10. 10.001412.34

10. 10.001412.34

10. 10.001412.34

10. 10.001412.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

10. 10.001413.34

614742-46-4 | RODGUS. Optiopent(| Industria). 1-4, 44.5.5.7-leashydro-4-methyl... (44.8.58).- (902). (Oh IDDE 19046).

2) HONES CONTEST 200 MS On STR
200:5589 HONES PAIL:EXT
PRESENTED OF CHARGE PAIL:EXT
PRESENTED OF CHARGE PAIL:EXT
PRESENTED OF CHARGE PRESENT SHALES
VIGLI JAM. Better, Extern Trian. Critician; Separra
VIGLI JAM. Better, Extern Trian. Critician; Separra
VIGLI JAM. Better, Extern Trian.
VIGLI JAM. Better, Extern Trian.
VIGLI JAM. Better, First Trian.
VIGLI JAM. PROSECTER
VICT. BETTER
PROSECTER
PROSECTER
TO SEPARRA
PROSECTER
TO SEPARRA
PROSECTER
PROSECTER
TO SEPARRA
PROS DOCHENT TYPE: LANGUAGE: FACTLY ACC. MIM. COUNT: PATENT DEPONANTOR: LL12 ANSWER/21,07 2
ACCESSION NÜNGER:
DOCUMENT HÜNGER:
TITLE: PATENT ASSIGNEE (S) : SOURCE: DIVENTOR (S):

30103 NO 2002-EP4727 AZ, BA, EB, BG, ER, BY, B, DH, DZ, BC, EB, SS, FT, G 13- JP, KB, KG, KG, KC, KG, KK, KC, KK, KC, KK, KC, KK 5 4 5 6 6 7 5 8 6 6 7

threshocytopenia; preparation of indatol-5-yl deriva. as selective glucocorticoid recepton

Ħ

65

H. 17 M. 18 OTHER SOURCE(S): GI

The title compde, [1; M. P. H. (GY13A) (unlembatituded alpy) (obstrain a contributed calpy) (obstrain a contributed calpy) (obstrain a contributed calpy) (obstrain a contributed calculation and advantage at the title in a contributed calculation (advantage) (advanta

ociogical activity); SPM (Synthetic preparation); or use); NDC (Stological study); PEP USES (thes) of 4-phenylpyrrologyrishidinediones as A2 adenosine receptor

6 6

691

May 16, 2007

desdes-Oral Acristy); SPM (Symbetic preparation); accompanies accepted acted); PESP (USES (Uses) (USES (Uses)) accepted accepted acted accepted acted accepted accept

A-1 804

1-1

 \mathbb{Q}

44498-40-2 NCAPLES

Personalization (3,7:-(metrylenable (3)-benzinidazole-5,2-diy)-4,1-phrylenalization-strongy))bis-(9CI) (CA INDEX NOSE)

PAGE 1-A H. C.S.

PAGE 1-8

DI 444916-68-9 HCAPLUS

5

THERE ARE 12 CITED REFERENCES AVELCABLE RECORD. ALL CITATIONS AVAILABLE 2 REPRESENCE COUNT.

Part of the control o LL2 ANSWER 22 OF 2 ACCESSION FUNDER: DOCUMENT NUMBER: TITLE:

DIVENTOR(S): PATENT ASSIGNER(S): SOURCE:

DOCUMENT TYPE: LANCUAGE: FAMILY ACC: NUM. COUNT: PATENT DIFORMATION: OTHER SOURCE (S):

MARPAT 137:150264

2

May [6, 2007]

St. Pluorens - 1-carboxande, N.N.* (methylenebia (Bi-benzinzlenable 5, 2-diy).

4, 1-phanylene) blas (5-cac- (942)) (CA. Index NAS)

PAGE 1-A

PAGE 1-8

No. 44494-449 MORRAN OR -Colonizamilent edd, 7,7'-[swky]erseks(W-benninderole-5,2-diy]-4,1-pumy(smesso)[his[s-hydroxy-192]] (CA. HORK MARS)

PAGE 1-A

9-1 XOV4

PR 44498-70-3 HCAPLES
OF Parameticate setd, 2, 2'-(oxybis(4,2-phanylane-1H-benzimidazole-2,5-Oxybiaincentbomy, 1) his- (OX) (OX 10035 NAS)

10038.22 Man 16.2007 custyric activity, e.g. custyric activity, e.g. custyric activity, e.g. custyric activity of e.g. I are described.

TO MAIR Proposition and biol. activity of e.g. I are described.

C. 1-12 (formacology)

TO Activity Constitution (1): 28

If Paradat Alberd

If Paradat Alberd

If Alberd

[methylenebis(1H-benzimidazole-5,2-diyl)]bis- (9CI) de 3-7 *22-73-24 f (Phanesological activity); ECT (Reactant); SPU stic preparation); TM (Theopentic and); BIO(618) ; PZET (Preparation); DAT (Restrant or respect); USES (Use) mi-1,-2-20; derivative preparation and use as beparames inh

BB 4823-19-6 ECAPLUS ON 1H-benizaldarol.5-sailse, 2.2 - (coydi-4.1-pbenylens)bis- (903) (CA DUEK MARE)

Ε

T 3H-11

 \mathbb{R}

-amine, 2,2'-(1,4-phenylene)bis- (9CI) (CA DUEX MAGE) and use as beparanase cological activity); TBD (Therapeutic logical study); USES (Uses) ole derivative preparation and use as

RN 70500-05-9 HCAPLUS CN 1H-Benzfmldsrol-5-amins, 2-(4-aminophenyl)-6-methyl-NAME)

LL2 ANSWER 23 OF 23 & ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

NUMBER CONTIGET 300 ACC ON STREET STR

DIVENTOR (S):

Heiji Seika Kaisha, Ltd., Japan Peri Int. Appl., 162 pp. Perent Parent Japanese DOCUMENT TIPE:
LANCHAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION: PATENT ASSIGNEE (S) :

| NATION 160. | COD | DATE | APPLICATION 160. | DATE | DATE | APPLICATION 160. | DATE | APPLICAT

B1 20020917 US 2000-601176 JP 1998-19282 HO 1999-JP415 MARPAT 131:130008

OTHER SOURCE(S);

234011-13-1 EGNELIS
L-Alanins, 3-[4-[4-(10)-benim[datol-2-y]]-1-piperatinyl]benzoyl] minol[{piersyles/benzyles/benyl

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMA. EFERENCE COUNT:

* W. (combusticated Cat. 118); Oz. 1189; Oz. 1189; Oz. 1189; Unablaticated Cat. 1189; Oz. 1189;

INVENTOR NAME SEARCH

13 SEA FILE-HOLDER MENGEN FILLOGE ("SANDADOV I A"/AD OR "SANDADOV I A"/AD OR I A THE THREE TH

. d 123 fbib ab tot

MANAGEME CONTIGHT 1807 ACT ON THE CONTIGHT 1807 ACT ON THE CONTIGHT 1807 ACT ON THE CONTIGHT INCOME THE CONTIGHT INCOME ACT ON THE CONTIGHT INCOME. THE CONTIGHT INCOME ACT ON THE CONTIGHT INCOME. L23 ANSWER 1 OF 12 HCAPLUS
ACCESSION NUMBER: 2006:
DOCUMENT NUMBER: 144:2
HTTLE: New h LTHOR (S) SOURCE:

its of mail-mal, thromboposatia respice agents:s fin, we discuss the preliminary supjection of sensing we ithin this chemotype. ANILAME For Wis mans ANI to GITHD MERSOGS ANILAME FOR WIS RECORD. ALL CITATIONS ANALAME IN THE RE FORMAT As A novel bennimidated has been discovered structure-activity a REFERENCE COUNT: PUBLISHER: DOCUMENT TIPE: LANGUAGE: AB A novel be:

reparention of 1H-inidate(1,5-c)pyridin-3-y)
serding. Date A:: Glark, Tamey 3:: Descripserding. Date A:: Glark, Tamey 3:: Descripmentalite, Demis 8:

This Applies Compared Compared Compared
This Applies Tames A:

This Applies Tames COPTRICAT 2007 ACS on STM 120747 HCAPLUS Fuil-text L23 ANSWER 2 OF 12 H ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: PATENT ASSIGNER(S) SOURCE: DIVENTOR (S):

preparation of phenylpiperative deriva. as integrin ord) unaquants and blood platelet aggregation inhibitors for treatment of inteness inteness. 346-67-69-79 234060-80-79 234060-20-79

II. BAC (Biological activity or affactor, escapt advasa); BSU (Biological acudy, unclassified); BPM (Symbatic preparation); (Therepente use); BIGL (Biological acudy); PEEP (Preparation) (Therepente use); BIGL (Biological acudy); PEEP (Preparation) (Therepente use); BIGL (Biological acudy); PEEP (Breparation)

214000-27 4 HCMPLMS L. Alamina, - 154 (14 (14) benzinidazol-2-yl) -1-piperezinyllbenzoyllamino) -18-(perplanitosyl) - 1, 1-dimethylathyl ester (921) (ch. Indux NAS) eparation of phenylpiperatine derive. as integrin ord3 agonies and blood platelet aggregation inhibitors for treatment 2 5

DI 2140H-12-9 MONPAIN CH L-Alamino - 2-(14-(14-19H-benindden)-2-yl)-1-piperatinyllbensoy)|asino)-9-(Edwyddentosyl carbonyl)-- 1-disachylethyl asino (64 DIEE MAE)

Ē

DOCINENT TIPE: LANGUAGE: FAMILY ACC: MUM. COUNT: PATENT INFORMATION:

AL 20050210 AU 3004-241314

AL 20050210 CL 3004-2513101

EM TAR SET TO GL 311 THE LEG TO THE SET TO THE SET TO GL 311 THE LEG TO THE SET TO THE SET

THERE ARE 3 CITED REFERENCES AVALLABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAL

HCAPLUS COPTRIGHT 2007 ACS on STN 2004-531312 HCAPLUS FULL-TEXT 141:94-531 Preparation and formulation of

May 16, 2007	
10/538,252	etics
	MILIN

0/538 252

DIVENTOR (S)	: (2)				Manager 1	Monetics Searding, Dirk A.; Price, Alan T.;	4	-	12	3	5	3						
				į	100	Server, agar	b											
PATENT ASSIGNCEB(S):	SSICHER	: (2)		į	ä	Smithkline Beecham Corporation, USA	ĕ	ğ	Ě	rat	ġ	ś						
SOURCE:				Ę	ä	PCT Int. Appl., 19 pp.	4	•	ė									
				8	ä	CODEN: PIXON	Ç.											
DOCUMENT TYPE:	TEPE			Patent	描													
LANGUAGE				ğ	English													
FAMILY ACC. NUM. COUNTY	CC. MUM.	8	Ë	-														
PATENT INFORMATION:	NPORMATI	ä																
FAT	PATENT NO.			ē		pATE		-	APPLICATION NO.	5	8	ğ		8	100			
		-		i		:	;	•		1	:	1	ł	٠		:		
8	WO 2004054515	515		2	•	20040701	100	•	WO 2003-US39633	20.00	20.00	3		~	20031212	57		
3	WO 2004054515	\$15		3		20041118	=											
	ž.	ġ	į	ă,	ž	BA, BB, SR, B	33	82	ð	ð	8	ð	82, CA, CA, CO, CB, CB, DR, DZ, EC,	Ä	ž	ដ		
	8	ġ	ij	Ĕ,	Š,	À	ď	ä	ដ	Ė	è	Ď	ż	ž	i	5		
	77	ž	Ŷ	Ř	è	ğ	ğ	ž	Š	Ė	Ę	ġ	ŝ	g	ř	ť		
	5	9	5	Š	Ĕ	វ												
	EN: BW,	88. QH.	Ď	Ė	ä	ă,	7	'n	SL. 52, 77, UD, Z	\$2,	Ľ	ġ	ZH. ZH. AK. AZ.	ř	ž	į		
	BT,	ğ	ij	ė	3	ij	Ĕ	ť	Ħ	ģ	ð	ť	ť	Ħ	ř	H		
	23,	Ľ	Ë	g	ø	5	Ħ	E	3	ř	Ę	Ė	õ	ij	\$I,	Š,		
	Ë	,	2	b	8	ť	ð	š	ð	8	ð	. 4	Ř	ij	ä	Ė	2	
N	AU 2003297925	25		7		20040709	209		AU 2003-297925	6	979			Ã	20031212	212		
ā	EP 1581527			3	•	20051005	80	_	EP 2003-796996	5	3	ž		ñ	20031212	212		
	R: AT, 318, CH, DS, DK, ES, FR, GB, GB, 117, LI, LU, KL, SR, MC, PT,	38	ð	8	ř	រា	č	ð	Ė	Ë	ä	3	Ä	ij	¥	Ė		
	Ħ	SI,	5	3	Ė	8	Ę	Ė	į	ř	ģ	ť	Ħ	Ę	š			
P,	JP 2006514951	151		H		2006051	5	•	JP 2004-560836	š	109	ž		ñ	20031212	212		
3	US 2006084682	285		7		20060420	5	_	US 2005-\$38252	-50	332	22		ŕ	20050609	609		
PRIORITY APPLA INPO.	APPLA	0	-					_	US 2002-433482P	102-4	1334	127		2	20021213	213		

	_		5					
ACCESSION NAMES: 2001:99146 NCAPLUS FULL-14XY DOCHMENT SUBER: 140:42170	Preparation of arylatopyratoles as thrembopoietia mimetics	Seerding, Dirk A.	Smithkline Beecham Corporation, USA	PCT Int. Appl., 51 pp. CODEN: PIXXD2	Patent	English		
L23 ANSKER 4 OF 12 RCAP ACCESSION KINGER: DOCUMENT SCHOOLS:	3717	DAVENTOR (S):	PATENT ASSIGNEE(S):	SOURCE:	DOCUMENT TYPE:	LANGUAGE:	PANCLY ACC. MUR. COUNTS.	PATENT INFORMATION:

DATE 20030606 APPLICATION NO. DATE 20031218 8 3 PATENT NO.

BCAPLUS 2002:9 123 ANSWER 7 OF 12 H ACCESSION WINGER: DOCUMENT WINGER: TITLE:

17,151516

(antification of a phramosphore for peptidy)
miscale 2. Barrian design of upstidy)
miscale 2. Barrian design of upstidy of upstidy of upstidy of upstidy of upstidy of upstidy of upstide and upstide of upstide CORPORATE SOURCE:

ocidibar 19,221196

Codibar 19,221196

Codibar 19,221196

Codibar 19,221196

Copher FUBLISHER:
DOCUMENT TITE:
LAWTHOR:
OTHER SOUNCE (8):
AB The invention
based on a pl
discussed. I
the rapid exp

COULD COPILION ACT ON THE STATE OF THE STATE ACCESSION NUMBER: DOCUMENT NUMBER: TITLE:

CORPORATE SOURCE: SOURCE:

FUBLISHER:
DOCUMENT TIFE:
LANGLAGE:
OTHER SCHICK [3):
AB High-Larcupter
thremboyed schi
thremboyed schi
trapid optimize
The application
allowed for the
REFERENCE COURT:

OTHER GOLDCE (S):

NAME AND A SECOND ASSOCIATION OF A SECOND AND A SECOND ASSOCIATION OF A SECOND ASSO

HCAPLUS COPYRIGHT 2007 ACS ON STA 2003:193616 HCAPLUS PULL-16X1 ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: UTHOR (S):

he activity of infinite-speciments termonological command of in the presence (ROCCACO) and (I) perfectly being access (ROCCACO) and (I) perfectly being access (ROCCACO) and (ROCCACOO) and (RO Temporolated in patients with advanced non-small cell lang cancer with advanced brain attentions a place II must cell and with advanced brain attentions as place II must cell cell and the post Lung Cancer Group (1985).

E. F.; Prices, A.; Debruyer, C.; Legrand, C.; Departement of Cancel of Maryland, C.; Departement of Cancel Canal, Cana COMPOSATE SOURCE: PUBLISHER: DOCUMENT TYPE: LANGUAGE: AB This study SOURCE:

RECORD. ALL CITATIONS AVAILABLE IN THE RE

Glaxo Group 33 12 HOURTON CONTRIGHT 2007 ACT on 573

THE STATE OF HOURTED TALL-SAME
TRANSPORTED ALT ENTERTHEN

TRANSPORTED ALT ENTERTHEN COMMISSION TO THE STATE OF DOCUMENT TYPE: LANCUAGE: FAMILY ACC. NOM. COU PATENT DIPORMATION: PATENT ASSIGNEE(S) LOS ANSWER 9 OF 1 ACCESSION NUMBER: DOCUMENT MUMBER: TITLE: INVENTOR(S): SOURCE

| March | Marc 20051207 P 20000525 P 20000830 A3 20010524 W 20010524 2005-351686 2000-207084P 2000-228929P 2001-585703 2001-US16863 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 20000094557 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 ## 2000009457 PATEM NO.

OFMER SORTERION WARRY 137,6197 NO 2001-1828774 & 20011139

ADMINISTRATING SECTION OF THE SECTION and both groups of pictura twans assumed was possible the response was chemred in sither propose and the rundy was closed after the first step of secretal with the occubiance of a lack of thangeutic extivity of simple-agent secretary of simple-agent secretary of the step in NGCL.

18 THEREBORG COOM!

19 THEREBORG COOM!

19 THEREBORG COOM!

10 THEREBORG COOM!

10 THEREBORG COOM!

11 THEREBORG COOM!

12 THEREBORG COOM!

13 THEREBORG COOM!

14 THEREBORG COOM!

15 THEREBORG COOM!

16 THEREBORG COOM!

17 THEREBORG COOM!

18 THEREBORG COOM!

18 THEREBORG COOM!

19 THEREBORG COOM!

10 THEREBORG COOM!

10 THEREBORG COOM!

10 THEREBORG COOM!

10 THEREBORG COOM!

11 THEREBORG COOM!

12 THEREBORG COOM!

13 THEREBORG COOM!

14 THEREBORG COOM!

15 THEREBORG COOM!

16 THEREBORG COOM!

17 THEREBORG COOM!

18 THEREBORG COOM!

18 THEREBORG COOM!

19 THEREBORG COOM!

19 THEREBORG COOM!

10 THEREBORG COOM!

11 THEREBORG COOM!

12 THEREBORG COOM!

13 THEREBORG COOM!

14 THEREBORG COOM!

15 THEREBORG COOM!

16 THEREBORG COOM!

17 THEREBORG COOM!

18 THEREBORG COOM!

18 THEREBORG COOM!

19 THEREBORG COOM!

19 THEREBORG COOM!

10 THEREBORG COOM!

11 THEREBORG COOM!

11 THEREBORG COOM!

12 THEREBORG COOM!

13 THEREBORG COOM!

14 THEREBORG COOM!

15 THEREBORG COOM!

16 THEREBORG COOM!

17 THEREBORG COOM!

17 THEREBORG COOM!

18 THEREBORG COOM!

18 THEREBORG COOM!

19 THEREBORG COOM!

10 THEREBORG COOM!

15 THEREBORG COOM!

16 THEREBORG COOM!

17 THEREBORG COOM!

17 THEREBORG COOM!

18 THEREBORG COOM!

18 THEREBORG COOM!

19 THEREBORG COOM!

10 THEREBORG COOM!

10 THEREBORG COOM!

10 T | Martin and ARE N. CARLEL.

SECTION ALL CITATIONS ANALARE FOR BEACH.

THE PROOF ALL CITATIONS ANALARE FOR REP.

THE PROOF ALL CITATIONS ANALARE IN THE R. P.

THE PROOF ALL CITATIONS ANALARE IN THE R. P.

THE PROOF ALL CITATIONS ANALARE IN THE R. P.

THE PROOF ALL CITATIONS ANALARE IN THE R. P.

THE PROOF ALL CITATIONS ANALARE IN THE REP.

THE PROOF ANALARE ANALARE IN THE REP.

THE PROOF ANALARE DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COU
PATENT DEPORMATION: PATENT ASSIGNER(S) ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: DIVENTOR (S):

61

183

L23 ANSWER 10 OF 12 ACCESSION NUMBER: DOCUMENT NUMBER: TITLE: DAVENTOR(S):	2001	2001:416769 HCAPLUS	•		
DOCUMENT NUMBER: TITLE: DAVENTOR(S):			- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
TITLE: DIVENTOR(S):	135:33476	3476			
DIVIDITOR (S):	Prepa	Preparation of naphth[1	Preparation of naphth[1,2-d]imidazoles as	dazoles as	
	Lueng	Luengo, Juan I.;	Luengo, Jun I.; Duffy, Kevin J.; Price, Alen F.: Zhang, Libna	.; Price, Ales	
PATENT ASSIGNEE (S):	1	kline Beech	Smithkling Beecham Corporation, USA	48	
SOURCE:	PCT TOOOD	PCT Int. Appl., 90 pp. CODEN: PIXOD2			
DOCUMENT TYPE:	Patent	4			
LANCELACE: .	English	4			
FAMILY ACC. NUM. COUNT: PATENT INPORMATION:					
PATENT NO.	9	BLAS	APPLICATION NO.	No. DATE	×
	:	:			
WO 2001039773	4	20010607	NO 2000-0533432		20001206
15 m					
RM: AT, BE.	ក ដ	E. DK. ES.	CY, DB, DX, ES, FI, FR, CB, GP, DB, TT, LU, MC, MJ,	H, 17, 18,	C. M.
	;	20021002	EP 2000-984123		20001206
	ä	20061102			
B.	G. DB.	DX. ES. FR. C	80, 69, 11, LI, LU, NI,		SE. NO. PT.
Ľ	Ę,				
JP 2003515560	۰	20030507	JP 2001-541505		20001206
AT 344031	۲	20061115	AT 2000-984123		20001206
US 2003083361	7	20030501	US 2002-148945		2002002
US 4858630	22	2005022			
PRIORITY APPLIA. DIPO. :	-		US 1999-16913CP	۵.	19991206
			WO 2000-US33432	3	20001206
OTHER SOURCE (S):		MARPAT 135:33476			
All The title compds.	a. (2; R1-	-R5 - H. 002	[I; R1-R5 - H, COZRII, alkyl, etc. (wherein R11 - H, alkyl.	. (wherein R.	t - H, alky]
cyclosikyl, etc.); R6 = H, alkyl, cyclosikyl, etc.; R7, R8 = absent, H, alky,	38	1. alkyl. cy	cloalkyl, etc.;	K7. R8 - aber	mt. H. alky
etc.; m = 0-6; X = 5, O, NH, etc.; AR = (un) substituted cyclic or polycyclic	X • 5, 0,	MH, etc.; A	A . (un) substit	uted cyclic or	polycyclid
aromatic ring co	ontaining	fre 3-16 c	arbon atoms, or	tionally cont.	o soo Sujuju
more pateroacomy and their politically acceptable sails which are non- negitide TPO mimetics, and are useful in enhancing platelat production, were		d are useful	in enhancing	letelet produ	Tribu Mere
prepared and formlated.	rulated.	8.9.43	E.g., a 1-step synthesis of the title compound	of the title	репосто
MEPEREZICE COLMT: 3		THERE ARE	DIOL. GALA IOT COMPON. 1 WERE GIVEN. THERE ARE 3 CITED REPERENCES AVAILABLE FOR THIS	TES AVAILABLE	POR THIS
		EECOSD AL	RECORD. ALL CITATIONS AVAILABLE IN THE BE POPMAT	TABLE IN THE	PR POPMAT

syntaximatchiales as esceptibiles toward-state a natural set outpetity of prosecter a set outpetity of prosecter a set outpetity of set of set outpetity of set outpetity of set of set outpetity outpetity of set outpetity outpetity of set outpetity outpe HCAPLUS COPYRIGHT 2007 ACS ON STN 2001:667401 HCAPLUS FULL-text 136:102 L23 ANSWER 11 OF 12 K ACCESSION NUMBER: DOCHEST KAMBER: TITLE:

SOURCE: CORPORATE SOURCE:

FILE "HCAPLUS" ENTERED AT 11:47:31 ON 16 MAY 2007
4425 SEA ARB-ON PUN-ON 1.10(L) (BAC OR DNA OR PAC OR PKT OR THU)/FL

23 SEA ABB-ON PLUS-ON LL1 AND LA

FILE 'EDGISTRY' BYTHEM AT 11:45:49 OR 16 NAY 2007
11:40.5 ESA ABB-OR FULL-OR FORD-CO/ES
577 GS SGB-OL 585 SAU LA
6487 GSA SGB-OL 585 TOL LA

TILE TREATMENT DESCRIPTOR THE STATE OF THE S

8

10538252 May 16, 2007	SEARCH HISTORY	as d his notil	(FILE 'HOME' ENTERED AT 10:39:30 CM 16 MAY 2007)	ALIZE HEADER DEFENDED ALIZED AND	**************************************	(18 00 \$17 \$10 \$10 \$11 \$10 \$10 \$10 \$10 \$10 \$10 \$10	-/FIX or 71351-74-7(01 or 71351-04-7(01 or 71351-14-7(01	FILE "HOMPLUS" EMPTHED AT 10:39:58 ON 15 NAY 2007	D IALL RITERY E THRONBOCTTOPENIA/CT	IA 1994 SEA AMB-CHI PLU-CHI "BLCCOD, DISMASS (L) THEOREGATIOPENIARPT1.8	E THROMOCTTOPENTA/CT E 83-ALL	LS 1552 ABB FULLON "PLATELET (81.000) (L) DISEASE, THROHBOCTTUP	L6 11065 SEA ABS-ON FLU-ON L4 OR L5 OR THROMBOFFM? OR THROMBOCTTOPEN.
10/538.252 Mar 16, 2007	<pre>acetyl-1-piperationethyllphonylmethyll+4.8.11-til(est- bitoxycathomyl)- 14.8.1.i-tetrarexyp()ocetachomyllmethyll+4.8.11-til(est- yith Ril) gev bl 14.1.i-tetraryl-1-piperationethyllphonylmethyll-14.8.11. gev bl 14.1-til-til-til-til-til-til-til-til-til-til</pre>	REPERBACE COUNT: 10 THERE ARE 10 CITED REPERBACES AVAILABLE FOR THIS	RECORD, ALL CITATIONS AVAILABLE IN THE RE FOUND.										

Discussion throughout the indication of a indicator species gener in a table because the indicator of a factor that the indicator of a table because the indicator of a table of the core structure and adjustment of numerical manners and adjustment of numerical functionality resulted in the deriphogen of (c. o.c.): Subjustment of numerical could be subjust of indicator approach of the indicator of t

1311:1923 of tetranacyclocuradecures and tegratical of tetranacyclocuradecures and tegratical of tetranacyclocuradecures and temporalists and

PATENT ASSIGNES(S):
PATENT ASSIGNES(S):
EXCHANGE
LANCINGS:
LANCIANCE:
PATENT TYPE:
TARGET TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TARGET
TAR

| March 18, | Marc

		•		187	
CACHET [Y -	J. Thus,	(tgr-butoxycarbon1) - 1,4,8,13-tetraaracyclocetradecane in MeGN followed by 6 (tgr-butoxycarbon1) - 1,4,8,13-tetraaracyclocetradecane in MeGN followed by 6 sirring to qive 90% [1,6,0) bromcomethyl) planylmethyl] - 4,8,11-tri (tert	butcoycarbomyl)- 14,8,11-tetrazacyclotetradecape. The latter was stirred with 1-acetylpiperazine and KGO3 in McOk at 50°for 1 h to give 86% 1-(4-(4-	-	
OH, alkony, halo, CO2H, carboxamido, (substituted) anyl and TGHZAGHZT [Y -	CCCR-4 receptor antagonists and thrombopoietis minerics (no data). Thus,	o, o	butcoversifomyl) - 14,8,11-tetrazarcycloretradecape. The latter was stirred with 1-acetylpiperazine and K3CO3 in MeON at 50°for 1 h to give 86% 1-[4-(4		
substituted)	opoletin mim	racyclotetrad	tetradecape.		
erboxamido, (ts and thread	(4. (bromometh	tetraggacyclo		
mlo, 002H, c	or antagonis	arbonyl) 1.	1) - 16,8,11-1 piperazine a		
OH, alkoxy, halo, CO2H, Carboxamido, (substituted) aryll and TGHZACH2T [Y -	CCCR-4 receptor antagonists and threehopoietin minetics (no data). Thus,	(tert-butoxy	butoxycarbony		

38.252 May 16, 20	L15 OR (713511-67-2/CEM OR 713511-68-3/CEM OR 713511-70-7/CEM OR 713511-71-8/CEM OR 113511-73-0/CEM OR 713511-74-1/CEM)	N 16 MAY 2007	N 16 MAY 2007	("Heerding D./au or "Heerding D A./au or "Heerding diek	("FRICE A"/AU OR "PRICE A I"/AU OR "PRICE ALAN I"/AU OR "PRICE ALAN IROWAS"/AU)	("SAFOROV I A"/AU OR "SAFOROV I G"/AU OR SAFOROV I U"/AU OR "SAFOROV I U"/AU OR "SAFOROV I OOS"/AU OR OR "SAFOROV IOOS"/AU OR OR "SAFOROV IOOS	(LIE AND (L19 OR L20)) OR (L19 AND L20) L21 OR ((L18 OR L19 OR L20) AND ?T/ROMBO?)	REMOVED) FILE HCAPLUS
10/538 252	Lide	FILE "HOAPLUS" ENTERED AT 11:50:56 ON 16 MAY 2007	PILE "HOACUS" LOGGETTON 14 MAY 2007 D LAT THE HOACUS" LOGGETTON 15 MAY 2007 TOT STREET HOACUS CONTROL TO 1 O LAT THE HOACUS CONTROL TO 1 O LAT THE HOACUS CONTROL TO 1	8 3	MICE.	8 8 8 9	ě	L2) 12 DUP RDI L22 (0 DUPLICATES RESOURD) ANSWERS 11-12* FROM FILE HCAPLUS D L23 LELE AN TOT